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Abstract
Non-traumatic intracerebral hemorrhage (ICH) is caused by a rupture of a 
brain artery leading to blood penetration into brain parenchyma. The
incidence of ICH is 10–22 per 100 000 persons per year worldwide. The 
prognosis is poor, with approximately 40% of the patients dying within one
month, and a large number of the survivors remaining with major disabilities. 
There is no proven effective medical or surgical treatment option, treatment
being mainly supportive in nature, with management in dedicated stroke units
reducing mortality and morbidity.
Major risk factors for ICH include hypertension and older age.
Hypertension is a well-known risk factor for ICH, shown in several case-
control studies. On many of the other potential risk factors, such as smoking,
diabetes, and alcohol intake, the results have been conflicting. In addition to
the chronic risk factors above, certain preceding triggering events may
temporally predispose individuals to ICH. However, data on such triggers in
ICH are virtually lacking.
Factors that take part in hemostasis and coagulation affect the prognosis
of ICH patients. Calcium plays an important role in coagulation, and
hypocalcemia has been associated with larger ICH volumes, severity of
symptoms, ICH expansion, whereas elevated calcium levels with better
outcomes, regardless of similar ICH volumes between hypo-, normo- and
hypercalcemic patients. However, there are some contradictions in the results
between different studies.
Older age, longer hospital stay, poorer motor function at discharge,
severity of the neurological deficits, use of antithrombotic medication, larger
and deep ICH, and intraventricular extension of ICH have all been reported to
associate with worse health-related quality of life (HRQoL) after ICH. These
parameters are mainly associated with the severity of the index ICH, and little
is known about the effect of other components of quality of life, such as mood
and anxiety.
We aimed to assess factors in our population-based cohort of ICH patients
that have been less studied, and gained less attention in earlier studies, taking 
into consideration novel factors such as feelings of depression and fatigue prior
to the index ICH. We wanted to assess whether triggering factors predisposing
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to the event exist in ICH. We also studied the effect of hypocalcemia on ICH
volume and mortality. In addition to traditional prognostic measures, we
attempted to assess quality of life and depression after ICH. We further
determined how occipital location, the rarest single-lobe location, affects the
outcome of the patients.
The prospective part of the study included patients admitted to the 
Helsinki University Hospital between May 2014 and December 2016. An
informed written consent was needed to participate (patient/proxy).
Hemorrhages related to tumor, trauma, ischemic stroke, vascular
malformations, and other structural abnormalities were excluded. The
patients were interviewed during hospital stay, and given structured
questionnaires. HRQoL at 3 months after ICH was measured using the
European Quality of Life Scale (EQ-5D-5L), and the 15D scale. The recovery
was evaluated by a combination of revisiting the electronic medical records and
a telephone call. Controls were matched by age and sex, and randomly selected
from the participants of the FINRISK study, a large Finnish population survey
on risk factors of chronic non-communicable diseases. Ages were matched in
5-year age bands. However, as the oldest FINRISK participants were 74-year-
olds, controls for the age group 75-84 were selected from the age group of 70-
74 years, and patients aged ˜85 years were excluded. The retrospective part
included a registry of 1013 consecutive ICH patients admitted to the Helsinki
University Hospital between January 2005 and March 2010, and the substudy
on hypocalcemia included 447 of the patients that had computed tomography
(CT) of the brain and serum/plasma ionized calcium taken within 72 hours of
symptom onset and within 12 hours of each other.
A total of 277 primary ICH patients were recruited to the prospective part 
of the study, of which 250 could be included in the risk factor analysis, 97 were 
able to provide consistent answers on the trigger questions, and 124 returned
the quality of life questionnaire. In the case-control study, the cases had more
often hypertension, history of heart attack, lipid-lowering medication, and
reported more frequently fatigue prior to ICH. In persons aged <70 years,
hypertension and fatigue were more common among cases. In persons aged
>70 years, the factors associating with the risk of ICH were premorbid fatigue, 
use of lipid-lowering medication, and overweight. None of the studied possible
triggers alone was more frequent during the hazard period compared to the
5
 
    
    
     
          
          
  
   
   
          
   
       
     
      




     
        
  
  
      
 
  
control period. However, when all physical triggers were combined, there was
an association with the triggering event and onset of ICH (risk ratio 1.32, 95%
confidence interval 1.01-1.73). Predictors for lower HRQoL by both EQ-5D-5L 
and 15D scales were higher NIHSS, older age, and chronic heart failure. Feeling
sad/depressed for more than 2 weeks during the year prior to ICH was a 
predictor for lower EQ-5D-5L, and history of ICH for lower 15D utility indexes.
Prior feelings of sadness/depression were associated with depression/anxiety
at 3 months after ICH.
In our study, we found that ICH patients had more often fatigue prior to
their ICH than the controls of similar sex and age. Hypertension was associated
with risk of ICH, as expected. Of the triggering factors present immediately
prior to the onset of ICH, physical triggers as a group were associated with the
onset time. Hypocalcemic ICH patients had larger ICH volumes than
normocalcemic patients. Their higher mortality rate is likely mediated through
larger ICH volumes. HRQoL after ICH was associated with the severity of the
stroke, comorbidities, and age. However, in our study, feelings of depression
before ICH had stronger influence on reporting depression/anxiety after ICH
than stroke severity-related and outcome parameters. Few were diagnosed
with depression, or had antidepressant medication. This information could be
used to identify patients at risk for post-ICH depression. Compared to other
ICH patients, occipital ICH patients were younger, had milder neurological 
deficits, smaller ICH volumes, more often structural etiology, and better
outcomes. The risk for epilepsy was similar with other ICH patients. Our






    
      
     
 
 




    
   
 













   





Ei-traumaattinen aivoverenvuoto aiheutuu aivovaltimon seinämän rikkoon-
tumisesta, mikä johtaa veren purkautumiseen aivokudokseen. Aivoveren-
vuodon maailmanlaajuinen ilmaantuvuus on 10-22 100 000 henkilöä kohti
vuodessa. Sairastuneiden toipumisennuste on heikko. Noin 40%
sairastuneista menehtyy kuukauden kuluessa, ja suuri osa selviytyvistä
vammautuu. Hoitokeinot ovat pääosin elintoimintoja tukevia, eikä
tehokkaaksi osoitettua lääkkeellistä tai kirurgista hoitoa ole keksitty. Hoito
aivohalvausyksiköissä kuitenkin vähentää kuolleisuutta.
Verenpainetauti ja korkea ikä kuuluvat aivoverenvuodon merkittäviin
riskitekijöihin, ja verenpainetaudin merkitys on osoitettu useissa tapaus-
verrokkitutkimuksissa. Monien muiden mahdollisten riskitekijöiden, kuten
tupakoinnin, diabeteksen ja alkoholin, osalta tuloksissa on ristiriitaisuutta.
Pitkäaikaisten riskitekijöiden ohella myös ns. trigger-tekijät, jotka vaikuttavat
tapahtumaa edeltävästi esimerkiksi verenpainetta nostamalla, voivat
mahdollisesti altistaa aivoverenvuodolle. Tällaisia laukaisevia tekijöitä ei ole
aivoverenvuotopotilailla juuri tutkittu.
Veren hyytymiseen vaikuttavilla tekijöillä on yhteys aivoverenvuoto-
potilaan ennusteeseen. Veren kalsiumilla on merkittävä rooli veren hyyty-
misessä, ja hypokalsemian onkin esitetty vaikuttavan aivoverenvuodon
kokoon ja kasvuun sekä oireiden vaikeuteen.
Korkeampi ikä, pidempi sairaalahoito, huonompi liikuntakyky, vaikeampi
neurologinen oireisto, antitromboottinen lääkitys, kookas ja syvä aivoveren-
vuoto ja verenvuodon purkautuminen aivokammioihin on yhdistetty
huonompaan elämänlaatuun aivoverenvuodon jälkeen. Tiedetään kuitenkin
vain vähän muista sairastumisen jälkeisistä elämänlaatuun vaikuttavista
osasista, kuten mielialatekijöistä.
Tavoitteemme oli tarkastella vähemmän tutkittuja aivoverenvuodon
riskiin, toipumiseen ja elämänlaatuun liittyviä tekijöitä, ottaen huomioon
myös ennen sairastumista koetut mielialatekijät ja uupumus, sekä sairastu-
mishetkelle mahdollisesti altistavia trigger-tekijöitä. Halusimme selvittää,
miten hypokalsemia vaikuttaa aivoverenvuodon kokoon ja kuolleisuuteen.




   
 
  
   
 
   
 
    
       
  
    
 
    
    






    
   
  
    
   






Tutkimuksen prospektiiviseen osaan rekrytoitiin Helsingin yliopistol-
lisessa sairaalassa aikavälillä 5/2014-12/2016 hoidettuja potilaita, jotka
antoivat kirjallisen suostumuksen (potilas/omainen). Aivoverenvuodot, jotka
liittyivät aivokasvaimeen, traumaan, aivoinfarktiin, vaskulaariseen malfor-
maatioon tai muuhun rakenteelliseen poikkeavuuteen jäivät tutkimuksen
ulkopuolelle. Potilaat haastateltiin sairaalassa oloaikana, ja he saivat
kyselylomakkeet täytettävikseen. Elämänlaatu kolmen kuukauden kohdalla
sairastumisesta selvitettiin EQ-5D-5L- ja 15D-lomakkein. Toipumista
arvioitiin sairauskertomusmerkinnöistä ja puhelinsoitolla. Kontrollihenkilöt
valikoitiin sattumanvaraisesti iän ja sukupuolen perusteella FINRISKI-
tutkimuksesta. FINRISKI on laaja väestötutkimus kroonisten tarttumattomien
tautien riski- ja suojatekijöistä suomalaisessa väestössä. Iät sovitettiin viiden
vuoden ikäjaksoin. Koska FINRISKIN vanhimmat osallistujat ovat 74-
vuotiaita, valittiin 75-84-vuotiaiden kontrollihenkilöt ikäryhmästä 70-74.
Iältään ˜85-vuotiaat potilaat jätettiin tutkimuksen ulkopuolelle.
Retrospektiivisessä osiossa käytettiin jo olemassa olevaa 1013 potilaan
aineistoa, johon on koottu kaikki Helsingin yliopistollisessa sairaalassa 
aikavälillä 1/2005-3/2010 hoidetut aivoverenvuotopotilaat. Ne 447 potilasta,
joilta oli otettu pään viipaletutkimus ja seerumin/plasman ionisoitu kalsium
72 tunnin kuluessa oireiden alkamisesta ja ko. tutkimukset 12 tunnin sisällä
toisistaan, osallistuivat hypokalsemia-tutkimukseen.
Rekrytoimme tutkimukseen 277 aivoverenvuotopotilasta. Potilaista 250
voitiin sisällyttää tapaus-verrokkitutkimukseen, 97 potilasta pystyivät
vastaamaan luotettavasti trigger-kysymyksiin, ja 124 potilasta palautti
elämänlaatukyselylomakkeet. Aivoverenvuotopotilailla oli verrokkejaan
useammin verenpainetauti, sairastettu sydäninfarkti ja/tai kolesterolilääkitys,
ja suurempi osa heistä raportoi uupumusta ennen sairastumistaan. Alle 70-
vuotiailla potilailla oli verrokkejaan useammin verenpainetauti ja uupumusta
ennen aivoverenvuotoa. Vähintään 70-vuotiaiden ikäryhmässä uupumus
ennen sairastumista, kolesterolilääkitys ja ylipaino lisäsivät riskiä sairastua
aivoverenvuotoon. Yksikään tutkituista trigger-tekijöistä ei yksinään ollut
yleisempi aivoverenvuotoa edeltävinä kahtena tuntina verrattuna vastaavaan 
ajankohtaan edellisenä päivänä. Fysikaaliset triggerit yhdistettynä assosioi-
tuivat kuitenkin sairastumishetkeen riskisuhteella 1.32 (95% luottamusväli 
1.01-1.73). Molemmilla tutkituilla mittareilla oireiston vaikeusaste, korkea ikä
8
 





   
  
    
  







     
 
   
 
  
      
  
   
  
ja sydämen vajaatoiminta ennustivat huonompaa elämänlaatua kolmen
kuukauden kohdalla sairastumisesta. Aiempi aivoverenvuoto ennusti 
huonompaa elämänlaatua 15D-asteikolla, ja sairastumista edeltävän vuoden
aikana koettu vähintään kahden viikon kestoinen masentuneisuus EQ-5D-5L-
asteikolla. Aiempi masentuneisuus assosioitui myös sairastumisen jälkeiseen
masennuksen ja/tai ahdistuksen tunteisiin.
Tutkimuksessa siis havaitsimme, että aivoverenvuotopotilaat kärsivät
saman ikäisiä ja sukupuolisia verrokkejaan enemmän uupumuksesta jo ennen
sairastumistaan. Oletetusti verenpainetauti assosioitui aivoverenvuodon
riskiin, ja fysikaaliset triggerit ryhmänä assosioituivat aivoverenvuodon
tapahtumahetkeen. Hypokalseemisten potilaiden aivoverenvuodot olivat
suurempia kuin normokalseemisilla, ja kuolleisuus suurempaa, mikä
todennäköisesti johtui kookkaammista vuodoista. Aivoverenvuodon jälkeinen
elämänlaatu assosioitui aivohalvausoireiston vakavuuteen, taustasairauksiin
ja ikään. Tutkimuksessamme merkittävimpänä tekijänä aivoverenvuodon
jälkeisiin mielialaoireisiin olivat kuitenkin mielialaoireet jo ennen 
sairastumista. Vain harvalla oli tiedossa oleva masennusdiagnoosi tai -lääkitys. 
Tätä tietoa voitaisiin hyödyntää, jotta potilaat, jotka ovat riskissä sairastua 
aivoverenvuodon jälkeiseen masennukseen löydettäisiin. Verrattuna muihin
aivoverenvuotopotilaisiin, takaraivolohkon aivoverenvuotoon sairastuneet
olivat nuorempia, lievempioireisia, ja heidän aivoverenvuodot olivat
pienempiä, ja vuodon etiologiana useammin rakenteellinen poikkeavuus. Riski 
sairastua epilepsiaan oli verrannollinen muihin potilaisiin. Tutkimuksemme




   
   
    
    
   
   
      
      
    
    
    
     
    
    
    
       
     
      
    
     
    
    
      
     
    
     
     
   




TABLE OF CONTENTS.................................................................................... 10
LIST OF ORIGINAL PUBLICATIONS............................................................. 12
ABBREVIATIONS ............................................................................................ 13
1 INTRODUCTION................................................................................... 15
2 REVIEW OF THE LITERATURE.......................................................... 17
2.1 Definition, incidence, and pathophysiology of ICH ................... 17
2.2 Classification ...............................................................................23
2.3 Different risk factors and etiologies............................................24
2.3.1 ICH and coagulation ......................................................26
2.3.2 White matter lesions ......................................................28
2.4 Triggering factors ........................................................................ 31
2.5 Diagnosis and patient evaluation................................................32
2.6 Treatment ....................................................................................34
2.6.1 Prevention of hematoma growth and rebleeding ..........34
2.6.2 General management of the patient ..............................36
2.6.3 Surgical treatment and combating the mass effect .......36
2.6.4 Treatment for the secondary changes............................38
2.7 Outcome, mortality and recovery ...............................................38
2.8 Secondary prevention ................................................................. 41
2.9 Measuring quality of life .............................................................42
2.10 Quality of life and depression after ICH .....................................43
3 AIMS OF THE STUDY...........................................................................45
4 PATIENTS AND METHODS .................................................................46
4.1 Publications I, II, and IV.............................................................46
4.2 Publications III and V .................................................................48
4.2.1 Patient selection .............................................................48
4.2.2 Neuroradiological data and analysis..............................49
10
 
     
   
   
   
    
    
    
    
    
     
    
    
    
    
    
     
    
    
    
     
 
  
4.3 Statistical analyses (all publications) .........................................49
5 RESULTS ................................................................................................51
5.1 Publication I .................................................................................51
5.2 Publication II............................................................................... 52
5.3 Publication III ............................................................................. 53
5.4 Publication IV ............................................................................. 55
5.5 Publication V...............................................................................62
6 DISCUSSION.........................................................................................64
6.1 Main results in the context of existing literature .......................64
6.1.1 Risk factors of ICH (I)....................................................64
6.1.2 Triggering factors in ICH (II) ........................................66
6.1.3 Hypocalcemia and ICH (III).......................................... 67
6.1.4 Quality of life after ICH (IV)..........................................69
6.1.5 Occipital ICH (V) ...........................................................70
6.2 Strengths and limitations ............................................................71
6.3 Implications for future research ................................................. 72
7 CONCLUSIONS..................................................................................... 74
8 ACKNOWLEDGMENTS........................................................................ 75
9 REFERENCES ....................................................................................... 78




              
  
            
   
 
  
      




     
    
   
  
      
 
    
 
  
List of original publications
This thesis is based on the following publications referred to in the text by their
Roman numerals:
I Sallinen H, Pietilä A, Salomaa V, Strbian D. Risk Factors of Intracerebral
Hemorrhage: A Case-Control Study. J Stroke Cerebrovasc Dis.
2020;29:104630.
II Sallinen H, Putaala J, Strbian D. Triggering factors in non-traumatic 
intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2020;29:104921.
III Sallinen H, Wu TY, Meretoja A, Putaala J, Tatlisumak T, Strbian D.
Effect of baseline hypocalcaemia on volume of intracerebral
haemorrhage in patients presenting within 72 hours from symptom
onset. J Neurol Sci. 2019;403:24–29.
IV Sallinen H, Sairanen T, Strbian D. Quality of life and depression 3
months after intracerebral hemorrhage. Brain Behav. 2019;e01270.
V Räty S, Sallinen H, Virtanen P, Haapaniemi E, Wu TY, Putaala J,
Meretoja A, Tatlisumak T, Strbian D. Occipital intracerebral
haemorrhage – clinical characteristics, outcome, and post-ICH epilepsy.
Acta Neurol Scand. 2020;10.1111/ane.13303. doi:10.1111/ane.13303.





    
  
    
   
  
   
   
  
   
   
  
  
   
   
    
    
    
     
   
     
   
    







      
   





AHA/ASA American Heart Association/American Stroke Association






CAA cerebral amyloid angiopathy
CI confidence interval
CMB cerebral microbleed 
CSF cerebrospinal fluid
CT computed tomography
CTA computed tomography angiography
DOAC direct oral anticoagulant
DSA digital subtraction angiography
DWMH deep white matter hyperintense signals
ESO European Stroke Organisation
FLAIR fluid-attenuated inversion recovery
GCS Glasgow Coma Scale
GWAS genome-wide association study
HA hypertensive arteriopathy
Hb hemoglobin
HICHS Helsinki Intracerebral Hemorrhage Study
HICHS-2 Helsinki Intracerebral Hemorrhage Study-2 
HMWK high molecular weight kininogen
HO-1 heme oxygenase 1
Hp haptoglobin








   
  
  
   
    
  
    
    
   
   
  
  
     
    
   




     
   
   
    
  
   
    
  
   








LMWH low molecular weight heparin
LPR1 low-density lipoprotein receptor-related protein-1
MRA magnetic resonance angiography
MRI magnetic resonance imaging
mRS modified Rankin Scale
NIHSS National Institutes of Health Stroke Scale
OAC oral anticoagulation




QoL quality of life
RCVS reversible cerebral vasoconstriction syndrome 
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1 Introduction
Non-traumatic intracerebral hemorrhage (ICH) is caused by a rupture of a 
brain artery leading to blood penetration into brain parenchyma. The
incidence of ICH is 10-22 per 100 000 persons per year worldwide, with a
higher incidence in low to middle income countries, compared to high income
countries[1]. The prognosis is poor, with approximately 40% of the patients
dying within one month, and a large number of the survivors remaining with
major disabilities[2]. There is no proven effective medical or surgical treatment 
option, treatment being mainly supportive in nature. However, management
in dedicated stroke units reduces mortality and morbidity[3].
Major risk factors for ICH include hypertension and older age.
Hypertension is a well-known risk factor for ICH, shown in several case-
control studies[4,5]. On many of the other potential risk factors, such as
smoking, diabetes, and alcohol intake, the results have been conflicting. In
addition to chronic risk factors, certain preceding triggering events may
temporally predispose individuals to stroke[6,7]. However, data on such
triggers in ICH are virtually lacking.
Factors affecting the prognosis of the patients include older age, lower
baseline Glasgow Coma Scale (GCS), higher National Institutes of Health
Stroke Scale (NIHSS) score, infratentorial location, ICH and intraventricular
hemorrhage (IVH) volumes and their growth, edema, hyperglycemia,
hydrocephalus, herniation, anticoagulation, and multiple hemorrhages[8–13].
Factors that take part in hemostasis and coagulation affect the prognosis of
ICH patients[14]. Calcium plays an important role in coagulation[15–17], and 
hypocalcemia has been reported to associate with larger ICH volumes, severity
of symptoms[18], ICH expansion[19], and elevated calcium levels with better
outcomes, regardless of similar ICH volumes between hypo-, normo- and
hypercalcemic patients[20]. However, between the studies are some
differences on how calcium affects the ICH volume and outcome.
Older age, longer hospital stay, poorer motor function at discharge,
severity of the neurological deficits by baseline NIHSS, use of antithrombotic
medication, large and deep ICH, intraventricular extension of ICH, and early 
worsening of the neurological deficit have all been reported to associate with 
worse health-related quality of life (HRQoL) after ICH[21,22]. These
15
 





   
  
     
     
       
   
            
   
    
        
    
  
     
 
   
    




parameters are mainly associated with the severity of the index ICH, and little
is known about the effect of other components of quality of life, such as mood
and anxiety.
In this study, we wanted to address ICH in a wide spectrum, taking into
account risk factors, triggering factors, parameters associated with hematoma
growth in the acute setting, as well as factors affecting the prognosis and post-
stroke quality of life in a prospective cohort of ICH patients in a single center
(one substudy also included retrospective patients to gain a larger number of
patients, and another substudy included only retrospective patients).
We aimed to analyze factors in a population-based cohort of ICH patients,
that have been less studied, and gained less attention in earlier studies, taking 
into consideration novel factors such as feelings of depression and fatigue prior
to the index ICH. We also wanted to find out whether triggering factors
predisposing to the event exist in ICH. As results between earlier studies on 
the association between hypocalcemia and ICH volume are somewhat
conflicting, we wanted to examine the effect of hypocalcemia in ICH volume
and mortality in a large consecutive cohort of non-traumatic ICH patients. In
addition to traditional prognostic measures, we wanted to assess quality of life
and depression after ICH, and addressed such factors affecting the subjective
quality of life that are not included in traditional outcome measures.
Gaining new insights on the risk factors, and factors affecting prognosis -
both physical and mental - will likely help in both preventing ICH as well as





   
    
    
      




   
   
   
    
    
 
 
   
2 Review of the literature
2.1 Definition, incidence, and pathophysiology of ICH
ICH literally means hemorrhage in the brain, and results from rupture of an
intracerebral artery when bleeding occurs into the brain parenchyma leading
to a hematoma. Additionally, the bleeding can rupture into the ventricles,
causing intraventricular hemorrhage. Of all strokes, approximately 10-15% are
caused by intracerebral hemorrhage[1].
ICH can be classified as primary or secondary. Non-traumatic ICH occurs 
without a predisposing head trauma. Primary ICH originates from a 
spontaneous rupture of small brain arteries, whereas in secondary ICH, there
is an underlying structural cause, such as a vascular malformation[23]. The
term spontaneous ICH is sometimes used, when no other cause apart from 
hypertension is found[24]. However, the classification of ICH is confusing, as
often times the knowledge on the underlying pathology and exact source of 
bleeding is unknown[24]. Thus, in different sources, the definitions somewhat
vary, and classifying the non-traumatic ICH as structural (ICH caused by an
underlying structural source) and non-structural may be convenient.
Figure 1. Example of a deep ICH in right hemisphere, with intraventricular extension.
17
 
   
  
      
         
       




          
   
         
      
    
  
     
  
   
  





   
      
    
 





     
Johann Jakob Wepfer based in Germany and Switzerland in the 17th century was 
the first to make note that stroke can be caused by either hemorrhage or
clotting[25]. In the next century, Italian Morgagni of Padua, worked on
postmortem studies and linked them with different clinical stroke subtypes[25,26].
Huge progress has been made in the diagnosis and management of stroke in
the past few decades. As recently as just almost fifty years ago, the standard
procedure to differentiate brain hemorrhage from ischemic stroke was a lumbar
puncture to detect blood in the cerebrospinal fluid. In later years, midline
echogram (transcranial sonography i.e. ultrasound-based imaging technique)
could be used to detect a displacement of the midline structures due to unilateral
lesion in the brain. Afterwards, the diagnostics of ICH were revolutionized by
advanced imaging techniques, such as computed tomography (CT) and magnetic
resonance imaging (MRI), which in addition to showing the hematoma itself,
may help in deciphering the etiology of the bleeding[25,27,28].
However, the advancement for specific stroke therapies concerns ischemic
stroke, and not ICH, with proven efficacy of drugs for secondary prevention of
ischemic stroke such as aspirin and anticoagulants, and intravenous tissue
plasminogen activator to lyse the intra-arterial clot in the brain artery, as well as 
more recently proven efficacy of thrombectomy to remove the intra-arterial clot[29].
ICH remains a devastating condition, and early mortality rates are
approximately 40%, with many of the survivors remaining disabled[2]. The
incidence of ICH is 10-22 per 100 000 persons worldwide annually, with a 
higher incidence in low to middle income countries, compared to high income
countries[1]. The incidence differs between ethnicities; in a meta-analysis and
systematic review, the incidence was comparable for white, black, Hispanic,
Indian, and Maori people, but two times higher for east and southeast Asian
people (51.8 per 100 000 person-years). The incidence is higher among males, 
and increases with older age. In some regions, the incidence has been reported
to decrease between years 1980 and 2008, possibly due to change in 
environmental factors, such as better blood pressure control[2].
Processes leading to ICH include amyloid angiopathy, structural vascular
malformations such as cavernomas, arteriovenous malformations (AVM),
cerebral venous thrombosis, vasculitis, ruptured aneurysms, ischemia with
hemorrhagic transformation, and trauma[14,30].
















































     
 
   
 
  
   
    
    
        
   
    
 
Table 1. Classification of non-traumatic ICH by underlying etiology. Adapted from
Textbook of Stroke Medicine (M. Brainin et al, 3rd Edition, Cambridge University 
Press, 2019, p.214).











transformation of brain infarct
Venous disease Acute intracerebral venous 
and/or sinus thrombosis









Vitamin K antagonists, FX-
inhibitors, F-II-inhibitors, anti-
platelet agents, thrombolysis 
with recombinant tissue 
plasminogen activator, etc.





Cryptogenic Cause suspected but not
detectable with currently 
available diagnostic tests
There are two types of vessel pathologies accounting for most primary 
intracerebral hemorrhages: deep perforator arteriopathy (hypertensive 
arteriopathy) and cerebral amyloid angiopathy (CAA)[31]. CAA is caused by ß-
amyloid deposits within cortical and leptomeningeal arteries[32].
Hypertensive arteriolopathy is characterized by loss of smooth muscle cells
from the tunica media, deposits of fibro-hyaline material, narrowing of the 
lumen, and thickening of the vessel wall; additionally, microatheromas and
microaneurysms are possible[33]. ICH caused by hypertensive arteriopathy
predominantly occurs in deep structures such as thalamus and basal ganglia
(nonlobar ICH), whereas CAA causes lobar cortical or subcortical
hemorrhages[34] as CAA affects cortical and leptomeningeal vessels[35]. More 
than 50% of primary ICH are thought to relate to hypertension, whereas CAA
accounts for approximately 30% of the cases[28]. However, patients may have
both pathologies co-existing; one study demonstrated that of patients with
19
lobar hemorrhages, only 16% had solely CAA, whereas 42% of the patients had 
both CAA and hypertensive arteriopathy[35]. 
Of the secondary causes of ICH, the most common structural etiologies 
leading to ICH include vascular malformations, neoplasms, and hemorrhagic 
infarction[36]. The prevalence of AVM – abnormal connection between 
arterial and venous systems without the normal capillary bed - is 
approximately 0.2% in adults, and the annual risk of hemorrhage in 
unruptured AVM is approximately 2%. The prevalence of cavernomas (cluster 
of thin-walled vessels without elastic fibers or smooth muscle, commonly 
surrounded by a rim of hemosiderin-laden gliotic tissue) is slightly higher than 
AVM, approximated 0.3-0.6%, but the risk of first bleeding is lower, around 
0.4-0.6% per year[36]. 
Expansion of the hematoma is common, occurring in up to one third of 
ICH patients, and most commonly during the first 24 hours[30]. Risk factors 
for hematoma expansion include anticoagulation treatment, spot sign in 
computed tomography angiography (CTA) suggesting on-going bleeding 
(Figure 2.), shorter time from ICH onset to computed tomography (CT), and 





  Figure 2. Brain CTA shows spot signs (arrow) indicating ongoing bleeding
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Following the primary injury caused by the mass effect, secondary injury to
the neurons is caused by edema surrounding the hematoma, inflammation,
and toxic biochemical and metabolic effects of the components of the clot and
its degradation[38]. Upon occurrence of ICH, microglia/macrophages are
rapidly activated. The microglia and macrophages are essential in
phagocytizing and clean-up of the hematoma[39]. However, by releasing
inflammatory factors and inducing a cascade of inflammatory reactions, they
contribute to the pathological changes in the blood-brain barrier (BBB),
edema and cell death. Activated microglia/macrophages appear in classically
activated M1 and alternative activated M2 phenotypes. Early after ICH
several blood components activate the microglia/macrophages into M1
phenotype. They express receptors such as toll like receptor 4 (TLR4) and
heme oxygenase 1 (HO-1) which help in clearing the hematoma. Additionally,
they produce proinflammatory mediators such as various interleukins (IL),
tumor necrosis factor alpha (TNF-°), oxidative metabolites and iron content,
which all exacerbate brain damage. In contrast, M2 may improve brain 
recovery by secreting factors that help in reducing inflammation, clearing cell
debris and tissue remodeling. Thus, inhibiting M1 and promoting M2 would
be useful for post-ICH recovery. TLR4 associates with inflammation,
leukocyte infiltration, and cytokine and chemokine production in the setting
of ICH. TNF-° and IL-1˛ are essential mediators of the neuronal damage 
after ICH[40]. The reactive microglia persist for 4 weeks, peaking at 3 to 7
days after ICH[41].
Additionally, oxidative stress – a condition with overproduction of free
radicals, essentially reactive oxygen species – plays an important role in
secondary brain injury after ICH, causing damage to the cells. Reactive 
oxygen species and nitric oxide are released as neutrophils are activated
within the inflammatory response. To eliminate free radicals, superoxide
dismutase is used, which causes redundant lipid peroxidation, and this in
turn changes the physical properties of cellular membranes, and alters 
proteins and nucleic acids, resulting in brain damage. Free radicals are also
formed by blood cell degradation products such as iron ions. Hemoglobin
and iron released from the red blood cells within the hematoma play an
important role in neuronal damage after ICH. The mechanisms of neuronal
injury are considered inflammation, oxidation, nitric oxide scavenging, and
21
 
    
     
  
 













        







   
      





       
   
   
edema. Thrombin, an important mediator in blood clotting, may also
participate in attracting inflammatory cells into the damaged area, and
promote edema formation[40].
Neutrophils infiltrate the site of the hemorrhage within 4 to 5 hours after
ICH, peaking at 3 days. In addition to producing reactive oxygen species, they
release proinflammatory proteases, and thus affect the BBB permeability and 
promote damage to the neurons. Apoptosis of the leukocytes within 2 days
after arriving at the site of the hemorrhage further activates microglia and
macrophages[41].
Inflammation, red cell lysis, and thrombin production lead to BBB 
disruption, and thus edema formation[41]. In experimental ICH models,
edema surrounding the hematoma has been found to develop in three steps.
First, within as early as the first hour after ICH, clot retraction, hydrostatic
pressure and plasma proteins cause edema, as serum moves from the
hematoma to the surrounding tissue. The second stage associates with
thrombin production via the clotting cascade, cytokines, matrix
metalloproteinases, reactive oxygen species, and complement mediators, and
the third stage with erythrocyte lysis and hemoglobin toxicity[41,42]. The first
stage is known as ionic edema, and the second and third are characterized by
vasogenic edema. The final stage is resolution of the edema[42].
Perihematomal volume has been shown to increase fastest during the first 2
days after ICH, and to peak toward the end of the second week[43], and the
extent of the edema to correlate with ICH volume[44]. However, the 
correlation with edema has been proposed to associate especially with the
surface of ICH, rather than volume itself, thus playing a relatively larger role
in irregularly shaped and smaller hematomas[45]. Edema surrounding the
ICH causes compression of the adjacent structures and may increase
intracranial pressure (ICP), and thus lead to hydrocephalus, or brain
herniation[44].
The hematoma dissolves within months. The microglia/macrophages
recognize the erythrocytes and their degradation products by their surface 
receptors, such as CD163 and CD47. Haptoglobin (Hp), present in human
plasma, binds to hemoglobin, forming a Hb-Hp complex recognized by CD163, 
expressed on monocyte-macrophage system, and thus leading to endocytosis 
of the complex. Hp and CD163 are upregulated by excessive Hb. Free heme
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released from ferric Hb under oxidative conditions, is toxic to the tissues.
Hemopexin (a heme scavenger protein) is able to bind to heme, and sequester
it to inactive form, to be catabolized in liver. The heme-hemopexin complex 
can also be endocytosed and degraded by lysosomal activity by cells that
express low-density lipoprotein receptor-related protein-1 (LPR1), which 
appears on the surface of various cells including macrophages, astrocytes,
neurons, hepatocytes and vascular endothelial cells. These two pathways have
been considered the most important endogenous scavenging pathways in
clearance of the hematoma following ICH[39].
The different components of secondary brain injury after ICH serve as 
potential targets for drugs to mitigate the brain damage caused by ICH.
2.2 Classification
ICH is often classified by location as either lobar, nonlobar, infratentorial or
mixed. Other classification by location is division to deep or lobar. Deep ICH
comprises ICH stemming from basal ganglia, thalamus, internal capsule,
cerebellum or brain stem[28]. The typical etiologies and risk factors differ
between different locations[46]. However, the information on the actual
bleeding source derived from the classification by location is limited[47].
SMASH-U is an ICH classification system developed in our center[14].
According to the classification, the ICHs are classified as Non-stroke (e.g.
trauma); Stroke, non-ICH (e.g. ischemic stroke with hemorrhagic
transformation); Structural lesion (structural vascular malformation at ICH 
site); Medication; Amyloid angiopathy (lobar, cortical or corticosubcortical
hemorrhage in a patient 55 years of age or older); Systemic/other disease (e.g.
liver cirrhosis); Hypertension, and Undetermined when the hematoma does
not apply to any of the other classes.
H-ATOMIC, another classification of ICH, includes 7 categories:
hypertension, cerebral amyloid angiopathy, tumor, oral anticoagulants,
vascular malformation, infrequent causes and cryptogenic, and takes 




    
 
   
 
        
    
     
          
       




      
 
  
       
      
       
   





   
         
  
  
   
    
       
  
     
   
2.3 Different risk factors and etiologies
Hypertension, smoking, excessive alcohol consumption, decreased low-
density lipoprotein cholesterol (LDL), low triglycerides, medication
(including anticoagulants, antiplatelets, selective serotonin reuptake 
medication, and sympathomimetic drugs), old age, male sex, Asian ethnicity,
CAA, cerebral microbleeds, and chronic kidney disease have been claimed
risk factors for ICH[34,49]. However, the results between studies on risk
factors have been partly conflicting. A systematic review that comprised of 14
case-control studies and 11 cohort studies stated age, male sex, hypertension,
and high alcohol intake as risk factors for ICH[4]. In the INTERSTROKE
study, a large international case-control study on risk factors of stroke with 
3059 ICH cases, hypertension, regular physical activity, diet, waist-to-hip
ratio, psychosocial factors, cardiac causes, and alcohol consumption were
associated with ICH, whereas current smoking, diabetes, and
apolipoproteins were not[5].
In a prospective cohort study of almost 40 000 women, smokers had a
relative ICH risk of 2.15 (individuals smoking less than 15 cigarettes a day) and
2.67 (individuals smoking 15 or more cigarettes a day) compared to
nonsmokers[50]. In a prospective cohort study of male physicians, the relative
risk for ICH was 2.06 for participants smoking daily 20 cigarettes or more,
compared to non-smokers[51].
The role of hypertension and usefulness of antihypertensive treatment is
outlined by the PROGRESS trial, which demonstrated a 76% reduction of
relative risk of ICH in individuals treated with antihypertensive medication,
compared to placebo in a follow-up time of 5 years[52]. Inadequate blood
pressure control has also been shown to increase risk for ICH recurrence[53].
In an Italian case-control study with 3173 ICH patients aged 55 years and older,
and 3155 controls, heavy alcohol intake associated with the risk of deep ICH,
but not with lobar ICH[54].
Of the anticoagulant agents, the newer direct oral anticoagulants (DOACs) 
have been proven as efficacious as warfarin in the prevention of ischemic
stroke in patients with atrial fibrillation, but to harbor a smaller risk for major
bleeding[55–58].
The role of statins and very low cholesterol levels as risk factors for ICH










       
   
    
       
       
     
    
     
  
   
   
          
    
  
   
    
   
     
     
     
      
     
   
    
        
patients demonstrated a reduction of overall stroke incidence among TIA and
ischemic stroke patients treated with high dose atorvastatin compared to
placebo. However, there was a small increase in the incidence of ICH in the
statin group[59]. In an analysis of 672 consecutive ICH patients, higher LDL-
levels were associated with lower likelihood of hematoma expansion and
decreased in-hospital mortality among ICH patients[60]. In a meta-analysis 
from 2012, there was no significant increase in ICH among statin users, and
ICH risk was not associated with the achieved LDL levels or the degree of LDL
reduction. Total stroke risk was reduced in the statin treatment group[61]. In
a recent meta-analysis of 39 studies and almost 300 000 patients, lipid-
lowering therapy was not significantly associated with increased ICH risk when
primary and secondary prevention were combined[62]. In secondary 
prevention trials, lipid lowering was associated with an increased ICH risk with
an odds ratio (OR) of 1.12 (95% CI 1.00-1.38). However, the estimated benefits
in lowering the risk for ischemic stroke were evaluated to greatly exceed the 
risk for ICH[62]. Statins have even been considered possibly having
neuroprotective effects in ICH by targeting secondary brain injury pathways in
the surrounding brain tissue[63].
As ICH is not just one entity, but has different underlying vessel
pathologies, the risk factors in those different underlying pathologies also
differ. Martini et al. studied risk factors according to the location of ICH: APOE
(apolipoprotein E) e2 or e4 genotype was associated with lobar ICH, whereas 
hypertension was associated specifically with nonlobar ICH[46].
Knowledge on the genetic contributors of ICH is still limited. Incidence
of ICH differs between ethnicities[64]. A genetic association study with 2189
ICH cases and 4041 controls estimated heritability of 45% for ICH, 70% for
the CAA-related ICH, and 35% for the hypertension-related ICH. Also in that 
study, APOE e2 or e4 genotype was shown to associate with CAA-related
ICH[65]. A systematic review on risk genes for ICH including 64 articles,
identified 38 genetic loci variously associated with risk of ICH, hematoma
volume, and outcome. Only 8 of the studies had used genome-wide
association studies (GWAS), the others were candidate gene studies[66].
Additionally, there are some monogenic or familial diseases caused by rare
mutations, manifesting clinically as ICH, such as familial CAA, where usually 
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the APP (the beta-amyloid precursor protein gene) is mutated, causing ICH
at a younger age[67].
2.3.1 ICH and coagulation
Factors that are involved in hemostasis markedly affect the prognosis of ICH
patients[14]. Disorders of coagulation, including anticoagulation drugs,
associate with larger hematomas, and promote ICH expansion, thus worsening
the prognosis of the patients. Reduced platelet activity has also been found to
associate with ICH growth and worse outcome[68].
In primary hemostasis, platelets adhere to endothelial proteins at the site
of injury, and themselves, and form a platelet plug, which is followed by
formation of an insoluble fibrin mesh that attaches into and around the platelet 
plug, created by the proteolytic coagulation cascade (secondary hemostasis).
Additionally, the fibrinolysis pathway and downregulation of the cascade are
essential, preventing excess thrombus formation[69,70].
The damaged vessel wall – as in the context of ICH - lets platelets adhere
to components of the extracellular matrix by their surface receptors, which 
causes them to activate, thus beginning the cascade of primary hemostasis. 
Activated platelets release agonists, which lead to activation of nearby
thrombocytes. This complex cascade leads to adhesion and aggregation of
platelets, and plug formation[70]. Also calcium plays an important role in
primary hemostasis. Various platelet activation agonists (e.g. subendothelial 
collagen and adenosine diphosphate (ADP)), and thrombin cause a rise of
intracellular Ca2+ as a result of the activated signaling cascades. The rise of
cytosolic calcium helps in further activation of the platelets and clot
formation[15,16].
Secondary hemostasis leads to cleavage of soluble fibrinogen to
insoluble fibrin by thrombin, a result of a cascade of activated serine
proteases. In healthy blood vessels, the cascade is inhibited. The secondary
hemostasis begins in two separate, but intertwined pathways, termed
intrinsic and extrinsic pathways. When blood gets in contact with exposed
extravascular tissues rich in tissue factor (such as fibroblasts), a complex of
tissue factor and factor VIIa leads to activation of factors X and IX, and
finally, Xa, in the presence of its cofactor Va, activates prothrombin to
generate thrombin[70]. Calcium also has an important role in this
26
 
    
  
    
 







   
   
 
 
       


















ADP, TXA2, serotonin 
- - Platelet receptors: GPVI, GPlbN/IX, allbf33, a2f31, 
PAR1, PAR4 
Vessel wall components exposed 
to blood: VWF, collagens, fibronectin, TF 
extracellular coagulation cascade, and activates various coagulation factors
to their active forms[17].
Thrombin acts in many important ways in the coagulation cascade. In
addition to cleaving fibrinogen to generate insoluble fibrin, it activates
platelets via cleavage of PAR1 and PAR4, activates factor IX, which then
activates factor XI, and activates cofactors VIII and V. The cascades work
together, forming positive feedback loops, and thus amplifying the
reactions[70]. 
Contributors of primary and secondary hemostasis are depicted in Figures
3 and 4.
Figure 3. Primary hemostasis; the platelet response. Platelet aggregation at the site of
injury is mediated by platelet receptors, platelet-derived agonists, platelet-derived 
adhesive proteins, and plasma-derived adhesive proteins. Fibrin deposition
around the resulting platelet plug is generated by the coagulation cascade. ADP
= adenosine diphosphate; TXA2 = thromboxane A2; VWF = von Willebrand factor.
Reprinted from Gale, A. J. Continuing education course #2: current
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Figure 4. Schematic overview of the blood coagulation cascade. The model is divided in
the intrinsic, extrinsic, and common pathway. F###: blood coagulation factors
denoted in Roman numerals. Active forms are denoted by a small ‘a’ added to
the Roman number. TF, tissue factor: PL, phospholipid; HMWK, high molecular
weight kininogen. Positive feedback loops by thrombin (dotted lines), FIXa 
(dashed dotted line), and FXa (dashed line) are indicated in grey. O indicates 
inhibition by activated protein C (APC) and tissue factor pathway inhibitor.
Reproduced from Spronk H, Govers-Riemslag JW, ten Cate H. The blood 
coagulation system as a molecular machine. Bioessays. 2003;25:1220-1228 with
permission from Wiley.
2.3.2 White matter lesions
The two most common types of small vessel pathology behind spontaneous
ICH – CAA and HA – have characteristic markers in neuroimaging, such as
cerebral microbleeds (CMB), white matter hyperintensities (WMH), and 
enlarged perivascular spaces[32]. Other features related to cerebral small
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vessel disease (SVD) are small subcortical infarcts, lacunes, and brain
atrophy[71].
WMH) – also known as white matter lesions (WML) or leukoaraiosis –
imply to the bilateral, and either patchy or confluent abnormalities seen in the
white matter of the brain in neuroimaging, either as areas of hypodensity in CT
or hyperintensity in T2-weighted or fluid-attenuated inversion recovery
(FLAIR) MRI sequences[72–74].
As discussed earlier, CAA typically associates with lobar macro- and
microbleeds, whereas HA with deep bleeds[75]. Post mortem studies have
shown that the histopathology behind WML changes is heterogeneous, and the
exact pathogenesis of the changes is not known. Damage to the tissue may
include myelin and axonal loss, astrocytic reactions, microglial responses,
lipohyalinosis, arteriosclerosis, vessel wall leakage, and collagen deposition in
venular walls, presumably caused by ischemia/hypoxia, hypoperfusion,
leakage in blood-brain barrier, inflammation, degeneration, and amyloid
angiopathy[76].
Charidimou et al. discovered that the WMH were common in both CAA
and HA. The distribution patterns differed between the two etiologies of SVD.
Multiple punctate subcortical FLAIR hyperintensities (multiple spots) were
more common in CAA-assumed pathology, whereas WMH around the basal
ganglia were more typical in HA[32].
WMH changes associate with cognitive decline, dementia, and risk for both 
ischemic and hemorrhagic stroke[74,77]. Additionally, they have been
associated with mood, gait, and urinary problems[33]. The severity of WMH is 
known to associate with worse outcome after stroke. After ischemic stroke,
WMH changes are associated with an increased risk for dementia, functional
impairment, stroke recurrence, and mortality[73]. After ICH, leukoaraiosis has
been demonstrated to associate with death and worse functional outcome,
however, there is some controversy between studies regarding functional
outcome, but it is noteworthy that the follow-up times are quite short, ranging 
from 28 to 90 days[78,79]. Accordingly, the possible associations between ICH 
volume and growth, and the degree of WMH changes have been controversial
between studies[80–83].
WMH can be seen as a rim of periventricular hyperintensity,




   
  
    
 




          
     
  





    
  
             
  
   
  
        
  
         
   
 
    
WMH separated from periventricular signal changes in brain MRI, and as 
hypointensity in brain CT[84]. The WMH can be graded in brain MRI or CT,
and different grading scales have been developed. The Fazekas scale is widely
used to grade the extent of WMH in brain MRI imaging. Fazekas graded the
periventricular hyperintensity (PVH) and deep white matter hyperintense
signals (DWMH) separately. PVH was graded as 0 = absence, 1 = “caps” or
pencil-thin lining, 2 = smooth “halo”, 3 = irregular PVH extending into the
deep white matter. DWMH was graded as 0 = absence, 1 = punctate foci, 2 =
beginning confluence of foci, 3 = large confluent areas[85]. FLAIR or T2 
sequences are best for analyzing WMH in MRI[86]. MRI is considered superior
to CT in detecting small WML, however, in detecting large lesions, it performs
equally[84].
There are a number of conditions that may mimic the WMH changes of
vascular origin in MRI, including multiple sclerosis and inflammatory causes.
Patterns of white matter disease, patient’s age, history and symptoms should
be considered when evaluating the changes[86].
There are several WML grading classifications in CT images. Van Swieten 
classification takes into account 3 different planes (through the choroid plexus
of the posterior horns, through the sella media, and through the centrum
semiovale). The WML severity is scored from 0 to 2, and anterior and posterior
parts are graded individually, severity being scored on the more affected side.
The score yields to an overall value of 0-4[87]. Modified van Swieten score
yields a total score of 0-8, as right and left sides are evaluated separately[88].
The Blennow score takes into account the extension (scoring 0-3) and intensity
(scoring 0-3) of the WML[89].
Cortical microbleeds (CMB) are small foci of chronic blood products within
the brain tissue. They are detected in MRI imaging, using special MRI
sequences (such as T2*) that are sensitive in detecting the hemosiderin
deposits, showing CMB as black or hypointense lesions, or signal voids[75].
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Figure 5. Examples of brain CT scans from patients with ICH with A) minor WML changes 
(modified van Swieten 2), and B) extensive WML changes (modified van Swieten
8).
2.4 Triggering factors
Case-crossover design – closely related to case-control design - can be used to
study temporal association between a certain event and its possible triggering
factors. In this type of study, each person serves as her/his own control. 
Control periods can be multiple, or single, e.g. the same time point on the 
previous day. The possible studied triggering factor should be transient, and
the event itself have an abrupt onset[90].
In an observational study on 848 ICH patients, in 30% of the patients the
symptoms began at rest, in 50% during light exertion, and in 20% during
moderate to vigorous exertion. In 27% of the patients, the researchers
identified a potential triggering event, such as strenuous exercise or sudden
transition from the supine to the erect position on awakening. However, there
was no comparison with other time points or controls. The study also included 
different etiologies, including brain tumors and vascular malformations[91].
In addition to chronic risk factors, preceding triggering events causing a
temporal predisposition to stroke have been identified. In a study on SAH
patients, drinking coffee or cola, vigorous physical exercise, nose blowing,
straining for defecation, being startled, anger, and sexual intercourse before 




     
  
   
       
    
 
  
   
  
   
 
 
    
     
      
 
  
      
    
 
   
  
     
   
   
  







the patients’ usual frequency of exposure, and were considered as trigger
factors to the event. The effect of the association was considered to be through
the events leading to rapid rise in blood pressure, and thus predisposing to
SAH[6,92]. In another cohort using case-crossover design, during the 2-hours 
following moderate to extreme physical exertion, the risk for aneurysm rupture 
was increased to 2.7-fold[93].
Sexual activity, exertion, coughing, sneezing, and straining at stool have
been found to associate with the timing of reversible cerebral vasoconstriction
syndrome (RCVS)[94]. Among ischemic stroke patients, moderate to vigorous
physical activity increased the risk of stroke to 2.3 fold within 1 hour of the
physical activity[7], whereas in another study, negative emotions were the
most common trigger during the 2-hour period before stroke onset (14.5% of
the 200 patients). Also anger and sudden posture change due to startling
associated with the onset time, whereas temperature change, positive
emotions, heavy eating, and physical exercise did not[95].
Many of the studied triggers are events that cause a rise in blood
pressure[96–98].
Other mechanisms considered in the setting of cardiovascular events and
triggering factors have been their physiological effect on blood pressure, heart 
rate, and myocardial oxygen demand, which are at least in part mediated by 
catecholamine secretion[99,100].
Data on triggering factors of ICH are virtually lacking. As the mechanisms 
of ICH and ischemic stroke differ, ICH caused by a rupture of a brain vessel, 
and ischemic stroke by an occlusion, the possible triggering factors and their
mechanisms are likely different.
2.5 Diagnosis and patient evaluation
The symptoms of ICH depend on the location and size of the hemorrhage.
Typical clinical presentation is an abrupt onset of neurological deficit[101]
such as left- or right-sided hemiparesis. Hemorrhagic and ischemic stroke
cannot be differentiated by clinical presentation. However, decreased level of
consciousness, vomiting, headache, seizures, and very high blood pressure
early in the course of the disease might imply to ICH[101]. Supratentorial
hemorrhages involving the putamen, caudate, and thalamus present with
contralateral sensory-motor deficits. The severity of the deficit associates with
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involvement of the internal capsule. Aphasia, neglect, and hemianopia indicate
dysfunction of the higher-level cortical structures. Clinical signs of brainstem
dysfunction in the setting of infratentorial hemorrhages include abnormalities
of gaze, cranial nerve abnormalities, and contralateral motor deficits. Ataxia,
nystagmus, and dysmetria may be present in cerebellar hemorrhages[23].
The mass effect caused by the bleeding in the brain parenchyma causes 
damage by compressing local structures, and leading to increased ICP[38,101].
Increase of global ICP can cause herniation, and cause compression of the
arteries, leading to secondary ischemia[38]. In posterior fossa hemorrhages 
the local compression can lead to obstruction of the aqueduct, leading to
obstructive hydrocephalus[38].
When suspected by symptoms, the diagnosis of ICH relies on rapid
neuroimaging with either CT or MRI[3,101].
CT is widely available, and fast to perform. In addition to ICH detection, it
provides information on possible intraventricular extension, edema
surrounding the hematoma, and midline shift with possible herniation or
brainstem compression[101]. CTA can be used to detect vascular
abnormalities[101] such as arteriovenous malformations or aneurysms. A spot
sign, i.e. enhancing focus or foci within the hematoma in the CTA source
images, is a predictor of hematoma expansion[102], and worse prognosis[103].
Size of the hematoma can be calculated in the CT images using the ABC/2
method, where A is the largest hemorrhage diameter, B the diameter at 90° to A, and
C the approximate number of CT slices with hemorrhage, multiplied by slice
thickness[104]. Alternatively, computer-based automated software such as Analyze or
Osirix can be used for hematoma volume calculation, however, the volumes by the
semiautomated measurement are a little smaller[105]. As ABC/2 assumes ICH as an
ellipse, in irregular shaped hematomas, ABC/2.4 formula has been proposed[106].
With suspicion of vascular malformations, digital subtraction angiography
(DSA) remains the gold standard, with sensitivity and specificity exceeding
99% in detecting vascular abnormalities. However, as an invasive method not 
so readily available, it is largely replaced by CTA and magnetic resonance
angiography (MRA)[107].
MRI is equivalent to non-contrast CT in the diagnosis of ICH[101],
however, it is not as readily available, requires a longer in-bore time, and is 





   
 





   
 
    






     
  
                     
altered consciousness or restlessness. MRI can aid in detecting underlying
causes such as tumor or hemorrhagic transformation of ischemic
stroke[28,101]. MRI performs better in detecting chronic hemorrhage[108].
Suspected stroke, including ICH patients, requires rapid transfer to
hospital that is prepared to treat stroke patients, and perform rapid
neuroimaging[3]. Level of consciousness (GCS), and baseline severity score
should be evaluated. NIHSS, commonly used in the evaluation of acute 
ischemic stroke, may be useful also in ICH, though a decreased level of
consciousness more commonly present in ICH patients may lessen its
usefulness[3]. GCS is commonly used for evaluating ICH patients in the acute
phase, informing about possible deteriorations.
A B 
Figure 6. Examples of A) a small deep left-sided hemispheric ICH, and B) a large right-
sided lobar ICH.
2.6 Treatment
2.6.1 Prevention of hematoma growth and rebleeding
There are few proven effective acute or preventive treatments for ICH[31].
Most ICH patients have elevated blood pressure (BP) in the acute stage[101].
Elevated BP has been shown to correlate with the risk of hematoma expansion 
and poor outcome[109]. Therefore, reducing arterial blood pressure in the
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hyperacute phase was suggested and tested in randomized controlled trials.
There is, however, controversy in the targeted blood pressure. The INTERACT-
2 trial, randomizing almost 2800 patients to target systolic groups of BP < 140
or < 180 mmHg, found no difference in death or severe disability at 90 days,
but patients in the lower blood pressure target group had better functional
outcomes[110]. The ATACH-2 study then randomized 1000 patients out of the 
planned 1280 to the same blood pressure targets. The study was terminated
early after an interim analysis showing no difference in death or severe
disability or outcome by mRS at 90 days, but showed increase in renal adverse
events in the intensively treated group[111]. In ATACH-2, the BP lowering was
fast and marked; average systolic BP over the 24 hours being 120-130 mmHg
in ATACH-2, and 135-145 mmHg in INTERACT-2. The studies did not find
reduction in hematoma expansion among the more actively treated groups.
Thus, the optimal BP target is still unknown. The American Heart
Association/American Stroke Association (AHA/ASA) guideline from 2015
comments systolic BP target < 140 mmHg as being safe[3], and the European
Stroke Organisation (ESO) guideline from 2014 states the same target as safe, 
and possibly superior to the target of < 180 mmHg[112].
Complete blood count, electrolytes, liver tests, creatinine, glucose, and
coagulation studies should be obtained[101], and severe coagulation factor
deficiencies or severe thrombocytopenia should receive appropriate
replacements[3]. If the patient is using oral anticoagulants (vitamin K antagonist
i.e. warfarin, or DOACs), their effect should be reversed. Prothrombin
concentrates (PCC) along with vitamin K are suggested for the reversal of
vitamin K antagonists. Antagonists for DOACs have been developed[113].
Recombinant activated factor VIIa (rFVIIa), used to treat hemophilia patients
and congenital FVII deficiency, can normalize international normalized ratio
(INR) rapidly, but does not substitute all vitamin K-dependent factors, and is
thus not recommended to be used routinely in the setting of vitamin K antagonist
(VKA) related ICH[3]. rFVIIa has also been tested in spot-sign positive
(indicating on-going bleeding) non-anticoagulant related ICH patients.
However, it did not improve radiological or clinical outcomes[114]. PCC have
some reversal effect on DOACs, and they are recommended to reverse the Xa
inhibitor group of DOACs in major bleeding such as ICH, if a specific antidote is
not available[113,115]. Protamine sulfate is recommended for patients with ICH
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occurring under heparin infusion or low molecular weight heparin
(LMWH)[3,116]. In a randomized controlled multicenter trial of ICH patients
having been using antiplatelet therapy before their ICH, where 97 patients
received platelet transfusion, and 93 patients standard care, platelet transfusion
increased the odds for death and disability[117], and cannot be recommended in
treatment of ICH. Tranexamic acid is used to reduce post-operative and
traumatic bleeding. This far, randomized controlled ICH-trials have not 
managed to show efficacy in improving outcome after non-traumatic ICH, 
although observational studies have signaled smaller hematoma growth with
tranexamic acid. There are still ongoing randomized controlled studies on
testing the efficacy of tranexamic acid on ICH patients[118,119].
2.6.2 General management of the patient
Hyperglycemia and hypoglycemia should be avoided, and seizures treated with
antiepileptic agents[3]. High blood glucose levels within 72 hours from
admission have been shown to independently correlate with worse functional
outcome[120]. Temperature management seems reasonable, but the target is
unclear. Intensive care or stroke units are recommended for initial treatment 
and monitoring of acute ICH patients. The patients should be screened for
dysphagia, and intermittent pneumatic compression is recommended for
prevention of venous thromboembolism[3]. In a meta-analysis of 1000 ICH
patients, early (from 1 to 6 days after admission) enoxaparin/heparin
treatment was associated with a reduction of pulmonary embolism rates, and
a non-significant reduction in mortality. No association was found with deep
venous thrombosis[121]. AHA/ASA guidelines recommend to consider low-
dose subcutaneous LMWH treatment after day 1 to 4 to prevent venous
thromboembolism, after cessation of bleeding has been documented[3]. In
SAH patients, a randomized single-center study comparing enoxaparine to
placebo, no beneficial effect on neurological outcome was seen in patients
receiving enoxaparine, but the rate of intracranial bleeding was higher in the
patients treated with enoxaparine[122].
2.6.3 Surgical treatment and combating the mass effect
There are ongoing trials on surgical treatment for ICH. At the moment, the role
of surgery is not clear[31], and the results whether surgery is beneficial or not,
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differ between studies[115]. A meta-analysis of 4 observational ICH studies
with 6580 patients, of which 578 patients with cerebellar hemorrhage, surgical
hematoma evacuation of a cerebellar ICH was not associated with better
functional outcome, but was associated with better survival, compared to
conservative treatment. Among patients with hematoma size of 12mL or
smaller, it was harmful[123]. A meta-analysis of 3 studies analyzing the efficacy 
of neuroendoscopic surgery versus craniotomy in patients with hypertensive
supratentorial ICH showed that neuroendoscopic surgery was associated with
decreased mortality and tendency toward lower complication rate compared
to craniotomy[124]. As large randomized trials failed to show beneficial effect
of open surgical evacuation in supratentorial ICH[125,126], MISTIE III trial
tested the efficacy of minimally invasive catheter evacuation followed by
thrombolysis for improving the outcome of ICH patients with supratentorial
hemorrhages. However, the trial did not improve the proportion of patients
with good outcome[127]. A randomized trial comparing medical management
and surgery among 119 patients, of which 72 (60.5%) received surgery, and the
rest the best medical treatment, surgery was associated with better survival, 
but not with better functional outcome[128]. Hemicraniectomy is another
surgical approach targeting to reduce the mass effect of the hemorrhage, and 
there is an ongoing randomized multicenter study (SWITCH) with the aim of
testing the usefulness of the operation[115].
IVH can cause blockage of the cerebrospinal fluid (CSF) circulation, and
lead to hydrocephalus, which may necessitate treatment with an external
ventricular drain, possibly accompanied with clot lysis by intraventricular rt-
PA injection[115].
The most common causes for elevated ICP in the context of ICH are the 
mass effect caused by the hematoma and IVH. Guidelines recommend ICP
monitoring with an intraparenchymal or ventricular device in patients with
coma, significant IVH and hydrocephalus, and evidence of transtentorial
herniation, targeting cerebral perfusion pressure of 50-70 mmHg.
Conservative measures to reduce the ICP are elevation of the head to 30º,
adequate sedation, and avoiding hyponatremia. Hyperosmolar therapy





       
    
 
 
   
    
 
      
  
     
  
  
   
  
    
   
   
     
  
    
    
 
   
    
    
 
        
   
  
   
 
     
2.6.4 Treatment for the secondary changes
Extravascular blood and its degradation products trigger processes that lead to 
further brain injury. These elements include calcium released from the cells,
thrombin-mediated activation of protease-activated receptors, fibrinogen,
heme and microglia activating transcription factors and proinflammatory
cytokines, the cascades leading to entry of systemic immune cells such as 
neutrophils, macrophages and lymphocytes[115]. At present, there are studies
assessing usefulness of substances that would reduce the toxic effects of 
hemoglobin (chelating agents), hemoglobin scavenging agents (such as
haptoglobin), and anti-inflammatory agents[31]. A recently published
multicenter futility-design randomized placebo-controlled phase 2 trial on
iron chelator deferoxamine mesylate in ICH patients concluded that
deferoxamine mesylate was safe, but treatment was not sufficiently promising
to support phase 3 trial[129]. Regarding secondary injury, the polarization of
microglia to the pro-inflammatory type M1 and anti-inflammatory M2 types
has been considered essential[130]. No proven therapy to reduce edema and
improve patient’s outcome exists yet[30].
2.7 Outcome, mortality and recovery
Approximately 40% of ICH patients die within the first months after ICH, and
many of the survivors have disabilities[2]. Compared to ischemic stroke, ICH 
patients have been shown to have less favorable outcome and more severe 
disabilities[130]. Older age, lower GCS, higher NIHSS, infratentorial location,
ICH and IVH volumes and their growth, edema, hyperglycemia, hydrocephalus,
herniation, anticoagulation, and multiple hemorrhages are predictors of
mortality after ICH[8,9,10,12,13]. Higher NIHSS predicts worse functional
outcome[131]. Functional dependence is shown to associate with age, lower
GCS, larger baseline ICH volume, hematoma expansion, and IVH[132].
There are altogether 19 published scores to predict prognosis after ICH
(mortality and/or functional outcome)[133]. The ICH Score is considered most
widely used and best validated[3]. The ICH Score takes into account five
characteristics: GCS, ICH volume with a cut point of 30 mL, age with the cut
point of 80 years, presence of IVH, and infratentorial origin of ICH,
infratentorial location having a worse prognosis. Total score ranges from 0 to
6 points. The ICH Score can be used to predict 30-day mortality, each increase
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in points associating with progressive increase in mortality[8]. A single-center
study comparing all those scores found that ICH-FOS, taking into account age,
NIHSS, GCS, ICH volume, intraventricular extension, glucose and ICH
location, performed only slightly better than admission NIHSS in predicting 3-
month and 12-month mortality[133].
A systematic review and meta-analysis of 122 longitudinal population-
based cohort studies that reported long-term (>30 days) outcome after
spontaneous ICH, found 1-year survival to be 46% and 5-year survival 29%.
The recurrence rate for survivors ranged between 1.3-7.4% per year (average
follow-up period was 1-7 years). The four studies that reported the risks for
recurrent ICH and ischemic stroke after ICH found the risks of ICH and
ischemic stroke similar[134]. In a Danish registry study of 15 270 ICH patients
between 1996 and 2011, ICH recurrence rate was observed as 8.9% within one 
year and 13.7% within 5 years. Surgical treatment and renal insufficiency were 
associated with increased recurrence rate, whereas antihypertensive 
medication associated with decreased recurrence rate[135]. In a cohort study 
identifying almost 6000 ICH patients in a population of more than 1.7 million
U.S. Medicare beneficiaries, the 1-year cumulative incidence of arterial
ischemic events (including a composite of ischemic stroke and myocardial
infarction) was 5.7% for ICH patients and 1.8% for patients without ICH, and
remained high with a hazard ratio of 6.7 after adjusting for confounders. In
their secondary analysis the risk for ischemic stroke was higher after ICH 
during a follow-up time of 6 months, but the risk for myocardial infarction was
not[136]. In a French cohort of 310 ICH patients alive at 30 days after ICH, 
20.0% had a major vascular event during a follow-up period of 5 years.
Ischemic events (including intra- and extracerebral events) were more 
frequent than hemorrhagic events, but there was a difference according to ICH
location – deep ICH associated with future ischemic events (ischemic events 
being 6 times higher compared to hemorrhagic events) and lobar ICH with
future hemorrhagic events[137].
When evaluating long-term outcome, in addition to mortality and
functional outcome, patient’s self-assessed quality of life, possible cognitive
impairment, psychiatric disorders, epileptic seizures, ICH recurrence and
thromboembolic events should be considered[132].
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Most studies use the 7-stage modified Rankin Scale (mRS) as a measure of
functional outcome, a favorable outcome usually defined as mRS ≤ 2 or
≤3[132]. There are few population-based studies on functional outcome after
ICH. A systematic review on outcome after ICH reported 32.8-42.4% of all
patients (53.7-83.7% of survivors) at 6 months, and 16.7-24.6% of patients
(53.8-57.1% of survivors) at 1 year to be independent (mRS ≤ 2)[134]. The
patients are at risk of ICH recurrence as well as other vascular events[137], and
new events are likely to affect the functional capacity of the patients.
Obviously, mortality and functional outcome have many predictors in
common[132]. In a cohort of 3255 Chinese patients, predictors for poor
functional outcome (mRS ≥ 3) were older age, admission NIHSS and GCS,
blood glucose, infratentorial location, ICH volume, and intraventricular
extension of the hemorrhage[138]. Lower scores measured by Barthel Index
(BI), indicating greater functional dependence had an association with older
age, lower GCS, baseline ICH volume, change of the ICH volume at 24 hours,
and IVH[139]. Patients with lobar hemorrhages have been observed to have a 
better functional outcome in comparison to deep/non-lobar hemorrhages, 
whereas no difference in relation to hemorrhage laterality was noted[140]. In
a study of long-term functional outcome of 131 young (< 50 years old) ICH 
survivors, 25% of the patients had poor functional outcome (mRS 3-5). Almost
half of the 131 patients (42.0 %) reported some level of one-sided motor
dysfunction, and 39.7% one-sided sensory dysfunction, 20.6% difficulties in
understanding or producing speech, 27.5% spasticity, 16.0% visual field 
impairment, and 10.7% diplopia[141].
Studies reporting return to work after ICH are scarce[132]. A Danish
register study on returning to work after stroke reported that 43.0% of 2272
ICH survivors were gainfully occupied two years after ICH occurrence. After
ischemic stroke, returning to work was more likely[142]. A Japanese study 
reported only 12.6% of 119 ICH survivors having returned fully to work at 1
year after ICH[143].
In a prospective study of 173 ICH patients, the mRS scores showed 
significant improvement between discharge and 3 months after ICH, but did
not differ between follow-up times at 6 and 12 months after ICH, compared to





     
    
   
      
  




           
  
  
      
        
   
    
   
    
   
  
   
  
  
         
  




     
 
  
Cognitive impairment in ICH patients have been thought to have multiple
mechanisms. It can be related to the underlying pathology causing ICH, arise
as a direct consequence to the brain lesion, and be associated with psychiatric
manifestations and other comorbidities[132]. In different cohorts of ICH
patients, cognitive impairment prior to ICH has been fairly frequent. A French
study on 417 ICH patients reported 29% of the patients cognitively impaired
prior to their ICH, 16% fulfilling criteria for dementia[145]. Another study 
reported 24.7% of the 166 patients cognitively impaired before ICH[146]. CAA 
and lobar ICH location associated with cognitive impairment in both studies.
A study investigating the incidence of and risk factors for early and delayed
dementia after ICH identified the incidence of dementia to be 19% 6 months 
after ICH and 5.8% per year afterwards in a cohort of 738 patients without pre-
ICH dementia. Risk factors for early dementia were larger hematoma size and
lobar location, whereas lower educational level, incident mood symptoms, 
increasing white matter disease severity, increasing lobar CMB burden and the 
APOE ε4 variant associated with delayed dementia. Only older age was a risk
factor for both early and delayed dementia[147].
Seizures in the acute setting (within 7 days of stroke onset) are more
prevalent after ICH compared to ischemic stroke[148]. Different studies
demonstrated around one in seven to ten of ICH patients to have seizures in
the acute setting[148–150]. In a Finnish cohort of 615 ICH patients surviving
longer than 3 months, 13.5% developed post-stroke epilepsy. New-onset
epilepsy had the highest incidence during the first year after ICH. Onset of
epilepsy associated with subcortical ICH location and early seizures[151].
2.8 Secondary prevention
After ischemic stroke, there are several means of secondary prevention such as
anticoagulant therapy, and statins[152,153]. The most important etiologic
factor to control after ICH is hypertension, however, no ICH specific secondary 
preventive medications exist[115].
A large proportion of ICH patients are using, or have an indication to
antiplatelet or anticoagulants drugs[115]. On top of recurrent ICH, ICH
survivors also have a risk for thrombotic events, such as ischemic stroke and
myocardial infarction, which raises concerns for the benefits and risks of
secondary prevention, such as antiplatelet therapy[134,154]. Especially
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patients with deep ICH have been noted to have a high risk for future ischemic
events[137], as well as older patients[136]. There are currently no randomized
controlled trials on resumption of OAC after ICH, however, several large
observational studies and meta-analyses exist[155,156]. A meta-analysis of
ICH patients with atrial fibrillation (AF) showed that the rate of ischemic
stroke exceeded the rate of recurrent ICH, and anticoagulation reduced the 
rate of thromboembolic complications and mortality, without causing an
increase in recurrent ICH rates[157]. In a study observing patients with or
without resumption of antiplatelets after mild or moderate ICH, there was no
significant difference in functional outcome or health-related quality of life at
90 days[158]. In light of current evidence, OAC resumption is considered
beneficial in decreasing thromboembolic complications and mortality. The
resumption may be safer in non-lobar than lobar ICH, and should be combined
with strict blood pressure control, and decided individually weighing potential
risks and benefits[155].
A meta-analysis of 8 studies with 6259 patients demonstrated an
overrepresentation of cerebellar ICH and IVH among OAC-treated ICH 
patients, and the authors conclude, that the mechanisms behind the 
underlying arteriopathy, pathophysiology, and bleeding pattern of OAC-
related ICH should be investigated more thoroughly[159].
2.9 Measuring quality of life
Defining quality of life (QoL) as a comparable measure is not easy. QoL has
been defined for example as of need satisfaction, health-related subjective
experiences, or psychosocial and physical well-being. As measuring QoL is
complex, a multidimensional approach is essential. According to a consensus, 
at least physical, functional, psychological, and social health dimensions
should be included in QoL assessment[160].
There are several scales to measure quality of life; few of them are stroke-
specific[160,161]. EQ-5D-5L[162] and 15D questionnaires are developed to
measure HRQoL, and they have been validated, and used in cohorts with 
stroke patients[163–167]. EQ-5D-5L is developed by EuroQol Group
(www.euroqol.org), and it defines health in terms of 5 dimensions: Mobility,
Self- Care, Usual Activities, Pain/Discomfort, and Anxiety/ Depression, each
of them with five response levels (no problems, slight, moderate, severe, and
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extreme problems). The EQ-5D-5L utility score is an index, which combines
those five dimensions into one score, which is calculated using population-
based preference weights. 1 represents perfect health, 0 death, and a negative 
value health states is considered worse than death.
15D is a 15-dimension (Mobility, Vision, Hearing, Breathing, Sleeping,
Eating, Speech, Excretion, Usual activities, Mental function, Discomfort and
symptoms, Depression, Distress, Vitality, Sex) health state descriptive 
questionnaire with five levels for each question, 5 being the worst and 1 the 
best possible. 15D results in a single index (15D score) on a 0-1 scale, 
representing the overall HRQoL. The index is calculated using a set of
population-based utility weights[166].
2.10 Quality of life and depression after ICH
Several studies assessed HRQoL after stroke[168–170], but few focused on
ICH patients. Also stroke patients with no or limited disabilities can experience 
reduced QoL[160,171,172]. Stroke patients may have difficulties in social
relations and mental functions, and experience poor quality of life, even when
they recover fully physically[173]. A Singaporean study found that stroke 
survivors had lower HRQoL than the general population even before the stroke,
and as expected the HRQoL further decreased after stroke[174].
Age, length of hospital stay, and motor function at discharge have been 
shown to predict HRQoL at six months after stroke[168]. In another study, the
strongest association with poor HRQoL three months after ICH was baseline
NIHSS ≥ 14 vs. < 14[21]. Additionally, older age, use of antithrombotics, larger
and deep ICH, IVH, early worsening of the neurological deficit, and completion
of the questionnaire by proxy responder associated with worse HRQoL[22].
After adjustment for disability and other relevant clinical factors, patient-
reported outcomes (including physical functioning, satisfaction with social
roles, pain interference, fatigue, anxiety, and sleep disturbance) have been 
reported to be similar between different subtypes of stroke (ischemic stroke, 
ICH, and SAH)[175].
Stroke and depression have a two-sided relation: risk of depression is
increased after stroke, and on the other hand, depression is a risk factor for
stroke[176]. Depression after ICH has been demonstrated to have a negative
effect on outcome unrelated to the severity of the initial symptoms[177].
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Psychiatric symptoms after ICH are less studied than after ischemic
stroke[132]. The most prevalent psychiatric manifestation in ICH-survivors
able to communicate was anxiety (prevalence 22% at three months, and 40% 
in a different cohort with median follow-up of 10 years)[134,178]. In different 
studies, the prevalence of depression has been found to be approximately a 
fifth of the ICH-survivors, ranging between 20.1% at three months[179], 15%




        
 
    
    
        
   
  
  
   
     
 
  
3 Aims of the study
We aimed to analyze factors in a population-based cohort of ICH patients, that
have been less studied, and gained less attention in earlier studies, taking into 
consideration novel factors such as feelings of depression and fatigue prior to 
the index ICH. We also wanted to find out whether triggering factors
predisposing to the event exist in ICH. As results between earlier studies on 
the association between hypocalcemia and ICH volume are somewhat
conflicting, we wanted to examine the effect of hypocalcemia in ICH volume
and mortality in a large consecutive cohort of non-traumatic ICH patients. In
addition to traditional prognostic measures, we attempted to assess quality of
life and depression after ICH. We further determined how occipital location,
the rarest single-lobe location, affects the outcome of the patients.
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4 Patients and methods
The study was conducted at the Helsinki University Hospital, which is an
academic teaching hospital and the only neurological emergency department 
with 24/7 service in Southern Finland, with a catchment area of 1.5 million
inhabitants.
4.1 Publications I, II, and IV
In publications I, II and IV, the patient cohort is a part of the Helsinki
Intracerebral Hemorrhage Study-2 (HICHS-2), a study focusing on genetic
and environmental risk factors for ICH. The study began in 2014, and is still 
ongoing. However, the substudy that included the more extensive interview,
questionnaires, and follow-up of the patients was terminated 31-DEC-2016.
We aimed to recruit all consecutive patients treated in our hospital,
presenting with possible spontaneous intracerebral hemorrhage immediately
after first imaging. Hemorrhages, which related clearly to tumors, trauma,
ischemic stroke, vascular malformations, or other structural abnormalities 
were excluded, and if one of those would be likely, further imaging was awaited
before recruiting the patient. If later studies disclosed a tumor, trauma, 
ischemic stroke, vascular malformations, and other structural abnormalities 
behind the ICH, a recruited patient was subsequently excluded from the
analyses.
To participate, the patient had to give an informed signed consent. If the
patient was able to give an informed consent but could not write due to for
example dominant hand paresis, the consent could be signed by a witness, who
was not related to the study. If the patient was not able to express his/her
opinion on participation, the consent could be given by his/her proxy.
The patients were interviewed using structured questionnaires, and
additional questionnaires were given upon recruitment. The interview
included questions on potential trigger factors, which were actions causing
Valsalva (lifting an object weighing over 20 kg, having to strain when
defecating/urinating, vomiting, coughing, sneezing, squatting for a long period
of time), abrupt change in position, heavy physical exertion, a heavy meal, a
sudden change in temperature, exposure to a traffic jam, and sexual activity.






   
        
   
         
   
 
  
     
   
     
  
   
       
 
   
    
    
  
         
 





    
  
such as medical history, social matters, profession, feelings of depression,
smoking, and alcohol consumption before ICH. If the questionnaire was not 
returned during the hospital stay period, it was sent to the patient’s home
address. Medical history was obtained using a combination of questionnaires
and medical records. The severity of the symptoms was graded by using NIHSS
and GCS scores on admission. The size of the hematoma was calculated by the
ABC/2 method, where A, B and C are the largest perpendicular measures of the
hematoma on CT images. The hematomas were classified using the etiologic
SMASH-U classification[14].
The patients were followed-up at three months and at one year after ICH.
At that time point, living and working status, mRS, and Barthel Index were
evaluated by a combination of revisiting the electronic medical charts and a 
telephone interview. At three months after ICH, the patients were sent 15D and
EQ-5D-5L questionnaires.
The controls (Publication I) were frequency-matched to cases by sex and
age, and randomly selected among the participants with no history of transient
ischemic attack (TIA) or stroke of the FINRISK study (collections from years
2002 and 2007). FINRISK is a large Finnish population survey on risk factors
of chronic non-communicable diseases, conducted by National Institute for
Health and Welfare of Finland[180,181]. The ages were matched in 5-year age
bands. As the oldest participants in the FINRISK study were 74-year-olds, the
controls for ICH patients aged between 75 and 84 years were selected from the
age group of 70-74 years. Patients aged 85 years and older (N=27) were 
excluded from the analyses. Three control persons were selected for each ICH
patient. The control participants had filled in structured questionnaires
including medical history, health-related lifestyle habits, and socio-economic
status. 
This study has been approved by the institutional review board and local
ethical committee of the Helsinki University Hospital (11.12.2013
311/13/03/01/2013 and 12.10.2016 HUS/1662/2016).
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4.2 Publications III and V
4.2.1 Patient selection
Publications III and V were retrospective analyses of the Helsinki ICH study 
(HICHS), which consists of 1013 consecutive ICH patients treated in the 
Helsinki University Hospital between January 2005 and March 2010. Patients
having ICH caused by tumor or trauma were excluded. Medical records were
used to obtain information on comorbidities, medication, and clinical status of
the patients. NIHSS and GCS were used to assess the severity of the symptoms. 
The Population Registry Centre provided the data on all-cause mortality (last
updated in November 2014). Foreign residents were lost to follow-up.
To be included in the analysis (publication III), ionized plasma/serum
calcium and admission CT of the brain had to be taken within 72 hours of
symptom onset, the two taken within 12 hours of each other. For wake-up
strokes, and if the symptom onset time was unclear, we used the time when the
patient was last known to be well as symptom onset time. Pure intraventricular
hemorrhages were few (n=5), and they were excluded.
447 Patients with calcium within 12 
hours of CT 
505 Patients with CT within 72 hours 
of symptom onset 
512 Patients with calcium within 72 
hours of ICH 




Figure 7. Cohort selection flow chart (Publication III). Permission to reproduce received 









    
   
    
     
     
  
      
 
  
   
   
    
 
      
    
  
         
  
   
 
        
  
     
  
     
   
For Publication V, the medical files of patients with occipital ICH were further
retrospectively analyzed on visual symptoms, rehabilitation, residual visual
function, vision-related disability, habitation, return to work, and ability to
drive a car, based on data reported in neurological, neurosurgical, or
ophthalmological outpatient appointments and from physiotherapists’,
occupational therapists’, and neuropsychologists’ evaluations, as well as from
the contacts to other specialties or to primary care. Visual field defect (VFD)
was evaluated with confrontation perimetry on admission, and residual defect
with standard automated perimetry after the acute phase or confrontation 
perimetry at discharge or at follow-up visits. The mRS could be categorized to
0-2 and 3-6 based on the retrospective data. We excluded patients with pre-
ICH epilepsy from the analysis of the incidence of post-ICH epilepsy. This 
study was an observational registry study, approved by the institutional review
board.
4.2.2 Neuroradiological data and analysis
Brain CT or MRI was used to detect ICH. ICH volumes were measured using
semi-automated planimetry (Analyze 12.0 software)[11,105]. The hematomas
were classified using the SMASH-U classification developed in our center[14].
Hemorrhage location was evaluated from the primary brain CT or MRI. The
affected anatomical structures were classified as ‘supratentorial lobar’,
‘supratentorial deep’, ‘infratentorial’, or ‘IVH’. If both deep and cortical
structures were affected, a neuroradiologist evaluated the assumed origin of
the ICH. If the origin could not be identified, the ICH was classified as ‘mixed’.
In the case of multifocal hemorrhages, the ICH was classified as lobar only if
all hemorrhages were lobar. The locations were determined by a 
neuroradiologist on the basis of established anatomical landmarks. To be
classified as occipital, the hemorrhage had to be limited to the occipital lobe.
4.3 Statistical analyses (all publications)
Statistical analyses were conducted using SPSS v.22, 24 or 25 (IBM, Armonk,
NY). In the analyses, two-sided probability (P) value < 0.05 was considered
significant. We expressed categorical variables as counts and percents (%),




   
 
       
 
     
 
    
  
        
     
       
  
    
 
  
(SE), and continuous variables not normally distributed as median and
interquartile range (IQR) values. The differences between the groups were 
calculated using the ˝2 test, the t test, or the Mann-Whitney U test as
appropriate.
For the trigger study (Publication II), case-crossover design was used, each
case serving as its own control, closely analogous to a matched pair case-
control design[90]. We used a single control period, as opposed to multiple
controls periods[182]. The hazard period for the triggers was defined as 0-2 
hours prior to the ictus, and the control period was the previous day between
the same time points. The ratio of the reported potential trigger factor during 
the hazard period, compared to the same period on the previous day, was used
to calculate the relative risks (RR) for each factor.
For publication IV (QoL), the multivariable analysis for depression/anxiety
was made using R Package ‘brglm’ to be able to handle the situation with no





   
    
 
  
          
 
       
       
       
         
  
   
          
    
   
5 Results
5.1 Publication I
Two-hundred and fifty patients of our study population fulfilled the study
criteria. Thus we selected 750 controls from the FINRISK study population.
Approximately half of the participants (128 cases; 51.2%) were under 70 years 
of age.
Multivariable analysis for risk factors of ICH is shown in Table 2. The cases 
had more frequently history of hypertension, heart attack, fatigue, lipid-
lowering medication, and higher education than their controls, when all age
groups were analyzed together. Overweight was more frequent among controls.
In the younger cohort (<70-year-olds) – with the cases more accurately age-
matched – hypertension, higher education, and fatigue were significantly more 
common among cases. In the older cohort, the ICH cases had higher education,
more fatigue prior to ICH, use of lipid-lowering medication, and were 
overweight. We also tested the same potential risk factors including age as a
continuous variable in the model for the older age group. Overweight was the 
only parameter which did not significantly differ between patients and controls.
Fatigue was not associated with heavy exercise among cases or controls in any 
of the age groups. There was no association between fatigue and ICH location.
51
 
        
 



























































































































    
  
      
  
Table 2. Multivariable analysis for risk factors of ICH. Reprinted from Publication I.
Permission to reproduce received from Elsevier.
Variable OR (95% CI) P value
Overweight (BMI >25)
All
Age < 70 years 









Age < 70 years 








All 1.60 (1.01, 2.54) 0.047
Age < 70 years 2.01 (1.07, 3.77) 0.029
Age ˜ 70 years 1.36 (0.70, 2.65) 0.369
History of heart attack
All 3.64 (1.03, 12.91) 0.046
Age < 70 years 7.64 (0.88, 65.97) 0.065
Age ˜ 70 years 3.91 (0.78, 19.54) 0.097
Lipid-lowering medication
All
Age < 70 years 







History of smoking (current or previous)
All
Age < 70 years 







High education (Bachelor/Master) vs.
lower education (primary school/high 
school/vocational school)
All 2.96 (1.78, 4.93) <0.0001
Age < 70 years 3.60 (1.79, 7.25) 0.0003
Age ˜ 70 years 2.13 (1.01, 4.49) 0.047
Fatigue often (vs. no/seldom; for cases 
prior to ICH)
All 4.54 (2.59, 7.95) <0.0001
Age < 70 years 3.50 (1.65, 7.42) 0.001
Age ˜ 70 years 6.07 (2.49, 14.80) <0.0001
Sad or depressed for more than 2 
weeks during the prior 12 months
All 1.59 (0.89, 2.83) 0.116
Age < 70 years 1.52 (0.72, 3.21) 0.267
Age ˜ 70 years 1.86 (0.73, 4.72) 0.191
ICH: intracerebral hemorrhage; OR: odds ratio; CI: confidence interval; BMI: body mass 
index 
5.2 Publication II
Ninety-seven patients (35.0% of our cohort of 277 ICH patients) were able to
provide consistent answers on the trigger questions, and thus eligible for the
analyses. The median delay between ICH onset and interview was 2 days (IQR




   
  
   
   
  
      
  






























       
 
        
 
        
 
        
 
 
       
        
  
 
       
 
 




       
     
 
   
 
The relative risks for the exposures of potential trigger factors during the
2-hour period preceding the ICH, compared to the same period on the day
before are shown in Table 3.
None of the studied possible triggers alone could be shown to affect the 
onset time of ICH. However, when actions causing Valsalva, physical exercise,
and sexual activity were combined as a physical trigger (i.e. factors that raise
blood pressure abruptly), we found it to be associated with the onset-time of
ICH (RR 1.32, 95% CI 1.01, 1.73).
Table 3. Relative risks for the exposures of potential trigger factors during the 2-hour
period preceding the ICH, compared to the same period the day before.





























96 41 17 7 24 48 1.32 
(1.01, 1.73)
Valsalva 78 23 7 4 16 51 1.15 
(0.85, 1.56)
Heavy exercise 95 13 6 2 7 80 1.44 
(0.87, 2.41)





94 0 0 0 0 94 NA








95 5 3 4 2 86 0.83 
(0.32, 2.15)
5.3 Publication III
In total, 178 hypocalcemic and 255 normocalcemic patients were included in
the analyses. Hypercalcemic patients were few, and comprised only 3.1% of the 
patients (n=14). Their median ICH volume was 6.5 mL (IQR 3.1-34.6 mL).
As shown in Table 4, in comparison to normocalcemic patients, 
hypocalcemic patients had (P<0.05) larger ICH and IVH volumes, were more 




   
  








     
     
      
     
      
 
    
     
     
     
     
     
    
  
    
     
      
      
     







       
     
  
and lower GCS scores, higher white cell count, C-reactive protein (CRP), and 
glucose on admission or in ambulance, and lower potassium, sodium, and
creatinine values.
Table 4. Characteristics of the patients and comparison of the radiological parameters,
laboratory test results, and outcome parameters that differed (P<0.05) between
the hypocalcemic and normocalcemic patients. Modified from Publication III.









Male 119 (66.9) 145 (56.9) 0.04 0/0
Dyslipidemia 23 (13.3) 55 (21.7) 0.03 5/1
Clinical admission parameters
NIHSS 19.0 (10.0-34.0) 12.0 (6.0-21.0) <0.001 0/0
GCS 10.0 (4.0-14.0) 14.0 (10.0-15.0) <0.001 0/0
Radiological parameters on 
admission CT
ICH volume, mL 30.2 (11.4-58.7) 16.8 (7.4-44.2) <0.001 0/0
IVH volume, mL 2.9 (0.0-22.5) 0.0 (0.0-8.7) <0.001 0/0
Admission laboratory results
White cell count, 109/L 9.7 (7.2-12.0) 8.0 (6.4-10.4) <0.001 2/3
CRP, mg/dL 5.0 (3.0-7.0) 4.0 (3.0-6.0) 0.017 2/2
Glucose on admission or
in ambulance, mmol/L
8.4 (6.9-10.8) 7.5 (6.3-9.5) <0.001 1/1
Potassium, mmol/L 3.7 (3.3-4.0) 3.8 (3.5-4.1) 0.018 6/5
Sodium, mmol/L 137.0 (135.0-139.0) 138.0 (136.0-140.0) 0.046 5/5
Creatinine, µmol/L 63.0 (54.0-82.5) 69.0 (58.0-85.8) 0.040 9/7
90-d-Mortality 93 (53.1) 87 (34.5) <0.001 3/3
ICH: intracerebral hemorrhage; NIHSS: National Institutes of Health Stroke Scale; GCS:
Glasgow Coma Scale; CT: computed tomography; IVH: intraventricular hemorrhage; CRP:
C-reactive protein
Data are presented as number of patients with percentages in parentheses,
median with interquartile ranges in parentheses, and mean with standard
error in parentheses.
Admission hypocalcemia was strongly associated with larger hematoma
volume (˛ =11.77, 95% CI 4.66-18.87, P = 0.001) in the multivariable logistic
regression model, as depicted in Table 5. Additionally, only older age had an
independent association with ICH volume.
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Table 5. Multivariable linear regression analysis for ICH volume predictors. Modified from
Publication III. Permission to reproduce received from Elsevier.
Variable ˛ (95% CI) SE P value
Missing
data
Hypocalcemia 11.77 (4.66-18.87) 3.62 0.001 0
Age (per year) 0.45 (0.16-0.74) 0.15 0.002 0
Use of statin prior to ICH 9.55 (-0.80-19.90) 5.26 0.070 11
Antiplatelet medication prior
to ICH
3.93 (-5.46-13.31) 4.77 0.41 1
Use of oral anticoagulant
(warfarin) prior to ICH
8.79 (-2.53-20.10) 5.76 0.13 0
Antihypertensive medication 
prior to ICH
3.41 (-4.51-11.33) 4.03 0.40 0
CI: confidence interval; SE: standard error; ICH: intracerebral hemorrhage
Hypocalcemic patients had higher three-month mortality in comparison to
normocalcemic patients (53.1% vs. 34.5%; P < 0.001) in the unadjusted 
analysis. However, as depicted in Table 6, hypocalcemia did not have an 
association with mortality in the multivariable logistic regression model after
adjusting for known predictors of mortality (OR 0.69, 95% CI 3.58-12.96,
P=0.13).
Table 6. Multivariable analysis for predictors of mortality at 90 days (n=427). Modified from 






Age, per year 1.04 1.02-1.06 <0.001 0
Volume of ICH, mL 1.03 1.02-1.04 <0.001 0
Volume of IVH, mL 1.04 1.03-1.06 <0.001 0
Infratentorial location of ICH 6.81 3.58-12.96 <0.001 0
Hypocalcemia 0.69 0.42-1.12 0.13 0
Anticoagulant medication 
(warfarin) prior to ICH
1.08 0.49-2.39 0.85 0
Multiple ICHs on imaging 1.72 0.59-5.04) 0.32 0
OR: odds ratio; ICH: intracerebral hemorrhage; IVH, intraventricular hemorrhage 
5.4 Publication IV
Four hundred and fifty-six patients with ICH were treated in our hospital during
the study period. Of those patients, 291 (63.8%) gave their consent for
participation in our study. Of the consented patients, 277 did not turn out to have
an exclusive secondary cause for ICH during the follow-up period. Fifty-six
patients (20.2%) died in the follow-up time of 3 months. We lost one foreign
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years (IQR 62.0-78.0 years), median NIHSS 5.0 (IQR 2.3-11.0), median GCS 15
(IQR 14.0-15.0), and the median ICH volume 8.9 mL (IQR 2.6-19.0 mL). The
questionnaire was returned by124 patients (56.4% of the survived patients).
The non-responders had more severe strokes by NIHSS (median 7.8; IQR 
3.0-14.8 vs. median 5.0; IQR 2.3-11.0; P = 0.018), as well as worse outcome at
three months: a larger proportion of the patients had mRS 3-5 (59.4% vs.
44.4%; P = 0.030), lower BI (median 95.0; IQR 35.0-100.0 vs. median 100.0;
IQR 85.0-100.0; P = 0.013), and they were less likely to live at home (54.7% vs. 
77.4%; P < 0.001). In regard to the other parameters the groups were similar.
In our cohort, the median EQ-5D-5L utility index was 0.590. Seven (5.6%) 
patients had incomplete answers, and thus the index was incalculable. The EQ-
5D index values vary from 0.909 (age group 25-34) to 0.583 (age group 75+), 
and the average value is 0.800 in the general Finnish population[183]. Our
cohort had a median 15D utility index value of 0.817. Sixteen (12.9%) patients
had incomplete answers, and incalculable index values.
The distribution of the EQ-5D-5L and 15D utility index values are depicted
in Figure 8.
A B 
Figure 8. The distribution of the A) EQ-5D-5L (n=117), and B) 15D (n=108) utility index 
values at 3 months after ICH. Reprinted from Publication IV. Permission to 
reproduce granted by publishing terms by Wiley.
As shown in Table 7, among the 117 patients with calculable utility indexes by 
EQ-5D-5L, lower HRQoL (ˆ 0.590) was associated (P<0.05) with consent 




         
   
         
   
  
 
   








    
    
    
    
     
    
   
    
   
 
  
   
    
    
    
    
     
    
     
     
    
     
     
     
     
     
     
    
    
  
        





asthma, frequently felt home-related stress, lower education level, higher
NIHSS and lower GCS scores on admission, higher baseline ICH volumes, deep
ICH location, DNR orders during hospital stay, lower BI, higher mRS, and the
patients were less likely to live at home at 3 months and 1 year. Higher HRQoL
had an association with cancer, including curatively treated forms. The 
detailed values including the parameters with no significant difference 
between the groups are represented in Table 1 of Publication IV.
Table 7. Comparison of the patients with low and high EQ-5D-5L utility index (n=117) † 
Parameters with significant difference (P<0.05) in univariate and/or multivariable
analyses are shown. Reprinted from Publication IV. Permission to reproduce





n= 58 P value
Age, y 70.0 (62.0-80.0) 70.5 (61.8-75.0) 0.195
Agreement by proxy 25 (42.4) 8 (13.8) 0.001
COPD/asthma 9 (15.3) 2 (3.4) 0.029
Chronic heart failure 7 (11.9) 1 (1.7) 0.061
History of cancer 9 (15.3) 18 (31.0) 0.043
No or little stress at home‡ 39 (72.2) 47 (90.4) 0.017
Sad or depressed for more than 2
weeks during the year prior to ICH‡
14 (30.4) 6 (11.1) 0.160
High education (Master or
Bachelor’s degree) ‡
10 (17.9) 20 (35.1) 0.038
NIHSS on admission 10.0 (3.0-15.0) 4.0 (2.0-6.0) <0.001
GCS on admission 15.0 (13.0-15.0) 15.0 (14.0-15.0) <0.001
Baseline ICH volume, mL 10.9 (4.5-23.0) 7.2 (1.9-16.2) 0.037
ICH location 0.001
ICH location, lobar 8 (13.6) 24 (41.4)
ICH location, deep supratentorial 48 (81.4) 30 (51.7)
ICH location, infratentorial 3 (5.1) 4 (6.9)
DNR orders in hospital 12 (20.3) 3 (5.2) 0.014
mRS at 3 months <0.001
mRS 0 0 (0.0) 5 (8.6)
mRS 1 2 (3.4) 11 (19.0)
mRS 2 16 (27.1) 34 (58.6)
mRS 3 15 (25.4) 5 (8.6)
mRS 4 16 (27.1) 3 (5.2)
mRS 5 10 (16.9) 0 (0.0)
Barthel Index at 3 months 90.0 (55.0-100.0) 100.0 (100.0-100.0) <0.001
Living at home at 3 months 36 (61.0) 55 (94.8) <0.001
Data are n (%), mean (SE), or median (IQR)
Abbreviations: mRS, modified Rankin Scale; ICH, intracerebral hemorrhage; COPD, chronic
obstructive pulmonary disease; NIHSS, the National Institutes of Health Stroke Scale; GCS,
Glasgow Coma Scale; DNR, do not resuscitate
† n=7 exclusion due to incomplete answers
‡ Missing data for sad or depressed for more than two weeks in 17 patients (14.5%), no or




     
 
  
        
    
     




      
    
    
     
    
     
   
 
   
    
    
    
     
    
     
     
     
     
     
     
     
    
  
 




       
  
Among the 108 patients with calculable 15D indexes, the lower scores
associated (P<0.05) with older age, antihypertensive medication, lower
education level, higher NIHSS, lower GCS, larger baseline ICH volumes, DNR
orders in hospital, higher mRS, and lower BI at 3 months, consent given by
proxy, and the patients having lower scores were less likely to live at home at 3
months and 1 year. The parameters with significant differences in either
univariate or multivariate analyses are depicted in Table 8.
Table 8. Comparison of the patients with low and high 15D score (n=108) †. The 
parameters with significant differences in univariate and/or multivariable
analyses are shown. Reprinted from Publication IV. Permission to reproduce
granted by publishing terms by Wiley.
Variable Low (ˆ 0.817) n=54 High (> 0.817) n=54 P value
Age, y 72.0 (62.8-80.0) 68.0 (60.5-75.0) 0.035
Agreement by proxy 27 (50.0) 6 (11.1) <0.001
History of any ICH 6 (11.1) 1 (1.9) 0.113
Chronic heart failure 6 (11.1) 1 (1.9) 0.113
Antihypertensive medication 34 (63.0) 23 (42.6) 0.034
High education (Master or
Bachelor’s degree)‡
9 (17.6) 22 (41.5) 0.008
NIHSS on admission 9.0 (3.8-15.5) 3.0 (2.0-5.0) <0.001
GCS on admission 14.5 (13.0-15.0) 15.0 (15.0-15.0) <0.001
Baseline ICH volume, mL 13.6 (6.2-24.5) 4.5 (1.7-16.0) 0.002
DNR orders in hospital 14 (25.9) 2 (3.7) 0.001
mRS at 3 months <0.001
mRS 0 0 (0.0) 4 (7.4)
mRS 1 2 (3.7) 11 (20.4)
mRS 2 14 (25.9) 33 (61.1)
mRS 3 15 (27.8) 4 (7.4)
mRS 4 13 (24.1) 2 (3.7)
mRS 5 10 (18.5) 0 (0.0)
Barthel Index at 3 months 92.5 (53.8-100.0) 100 (100.0-100.0) <0.001
Living at home at 3 months 33 (61.1) 52 (96.3) <0.001
Data are n (%), mean (SE), or median (IQR).
Abbreviations: mRS, modified Rankin Scale; ICH, intracerebral hemorrhage; NIHSS, the 
National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale; DNR, do not
resuscitate
† n=16 exclusion due to incomplete answers
‡ Missing data for high education in 4 patients (3.7%),
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Figure 9. A) EQ-5D-5L (n=117), and B) 15D (n=108) utility indexes across mRS groups at
3 months after ICH. Reprinted from Publication IV. Permission to reproduce
granted by publishing terms by Wiley.
Table 9 shows the multivariable regression analyses for lower HRQoL in both
EQ-5D-5L and 15D index values. Predictors for lower HRQoL in both measures
were chronic heart failure, higher NIHSS on arrival, and older age. Lower EQ-
5D-5L utility index was associated with feeling sad or depressed for more than




     
 
 




   
   
   
   
 
  
    
   
   
   
   
 
 
         
 





     
  
   
   
   
       
    
    
   
 
  
Table 9. Multivariable binary logistic regression analysis for predictors of decreased a)
EQ-5D-5L utility index, and b) 15D score at 3 months† Reprinted from Publication 
IV. Permission to reproduce granted by publishing terms by Wiley.
Variable OR (95% CI) P value
Predictor for decreased EQ-5D-5L utility
index‡
Chronic heart failure 18.12 (1.73-189.27) 0.016
History of cancer 0.20 (0.053-0.77) 0.019
NIHSS at arrival 1.28 (1.13-1.46) <0.001
Age per year 1.10 (1.03-1.16) 0.002
Sad or depressed for more than 2 weeks during 
the year prior ICH
10.64 (2.39-47.28) 0.002
Predictor for decreased 15D utility index§
Chronic heart failure 12.84 (1.31-126.32) 0.029
NIHSS at arrival 1.28 (1.15-1.44) <0.001
Age per year 1.09 (1.03-1.15) 0.003
History of any ICH 11.85 (1.01-138.90) 0.049
† 95 patients included in analysis due to missing data (EQ-5D-5L); 104 patients included in 
analysis due to missing data (15D)
‡ Adjusted for: agreement by proxy, mRS 3-5 prior to ICH, COPD/asthma, coronary artery 
disease, no or little stress at home, living alone, high education, GCS on admission, baseline
ICH volume, ICH location, DNR orders in hospital
§ Adjusted for: agreement by proxy, antihypertensive medication, living alone, occupational
status, high education, GCS on admission, baseline ICH volume, any neurosurgery, DNR
orders in hospital
Abbreviations: NIHSS, the National Institutes of Health Stroke Scale; ICH, intracerebral
hemorrhage
Table 10 shows comparison between the patients that reported having or not
having feelings of depression/anxiety at the time point of 3 months after the 
hemorrhage. Feelings of depression were more common among patients with
mRS 3-5 three months after ICH, dementia patients, patients with DNR orders 
in hospital and patients that had already felt sad or depressed during the
previous year before ICH. Only patient reported depression in the year prior to
ICH was an independent predictor for feelings of depression and/or anxiety at
3 months after ICH in the multivariable analysis (Table 11). Only 4 (3.7%) of 




   






   
    
    
     
     
    
     
     
     
    
     
      
    
     
     
     
    
    
    
     
      
    
     
    
      
    
    
    
    
     
     
     
     
      
 
   
       
    
     
     
     
     
     
     
    
      
    
    
     
    
  







Table 10. Comparison of the patients with or without reported depression and/or anxiety in 
EQ-5D-5L three months after ICH (n=122) †. Modified from Publication IV. 





anxiety n=54 P value
Age, y 69.5 (62.3-75.8) 72.5 (59.8-79.3) 0.335
Male 34 (50.0) 30 (55.6) 0.542
Agreement by proxy 18 (26.5) 18 (33.3) 0.409
mRS 3-5 prior to ICH 1 (1.5) 3 (5.6) 0.321
Diabetes 10 (14.7) 6 (11.1) 0.559
History of ischemic stroke 8 (11.8) 7 (13.0) 0.841
History of any ICH 2 (2.9) 5 (9.3) 0.239
COPD or asthma 4 (5.9) 7 (13.0) 0.212
Dementia 0 (0.0) 5 (9.3) 0.015
Coronary artery disease 4 (5.9) 8 (14.8) 0.100
History of atrial fibrillation 15 (22.1) 16 (29.6) 0.340
Chronic heart failure 3 (4.4) 5 (9.3) 0.464
History of cancer 15 (22.1) 13 (24.1) 0.793
Antiplatelet treatment 15 (22.1) 10 (18.5) 0.630
Anticoagulant treatment 11 (16.2) 15 (27.8) 0.120
Antihypertensive medication 35 (51.5) 29 (53.7) 0.806
Antidepressant medication 2 (2.9) 1 (1.9) 1.000
Sad or depressed for more than 2 weeks during the year prior to ICH‡ 6 (10.0) 15 (33.3) 0.003
Alcohol use (within 1 year prior to ICH)‡ 55 (83.3) 43 (81.1) 0.754
No or little stress at home‡ 53 (86.9) 37 (74.0) 0.085
Living alone 23 (33.8) 16 (29.6) 0.622
Married or registered relationship) ‡ 40 (59.7) 33 (63.5) 0.676
Occupational status, working 13 (19.1) 13 (24.1) 0.507
High education (Master or Bachelor’s degree) ‡ 21 (31.8) 10 (19.2) 0.123
NIHSS on admission 5 (2.3-9.8) 6 (2.0-13.3) 0.262
GCS on admission 15 (14.0-15.0) 15 (13.8-15.0) 0.683
Baseline ICH volume, mL 8.0 (1.9-16.4) 12.0 (4.0-21.9) 0.082
ICH location 0.555
ICH location, lobar 22 (32.4) 13 (24.1)
ICH location, deep supratentorial 42 (61.8) 38 (70.4)
ICH location, infratentorial 4 (5.9) 3 (5.6)
ICH evacuation/any neurosurgery 1 (1.5) 4 (7.4) 0.169
DNR orders in hospital 4 (5.9) 12 (22.2) 0.008
Deterioration (increase in NIHSS at least 4 points) within 1 week 
of ICH 
5 (7.4) 2 (3.7) 0.462
Acute myocardial infarction or heart failure within 1 week of ICH 0 (0.0) 2 (3.7) 0.194
mRS at 3 months 0.175
mRS 0 4 (5.9) 1 (1.9)
mRS 1 10 (14.7) 3 (5.6)
mRS 2 31 (45.6) 20 (37.0)
mRS 3 10 (14.7) 12 (22.2)
mRS 4 8 (11.8) 13 (24.1)
mRS 5 5 (7.4) 5 (9.3)
mRS 3-5 at 3 months 23 (33.8) 30 (55.6) 0.016
Barthel Index at 3 months 100 (91.3-100.0) 97.5 (80.0-100.0) 0.164
EQ-5D-5L utility index at 3 months‡ 0.711 (0.577-1.000) 0.517 (0.341-0.588) <0.001
15D score at 3 months‡ 0.885 (0.769-0.941) 0.770 (0.588-0.827) <0.001
Living at home at 3 months 54 (79.4) 42 (77.8) 0.827
Working at 3 months 2 (2.9) 2 (3.7) 1.000
Data are n (%), mean (SE), or median (IQR)
Abbreviations: mRS, modified Rankin Scale; ICH, intracerebral hemorrhage; COPD, chronic obstructive 
pulmonary disease; NIHSS, the National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale;
DNR, do not resuscitate
† n=2 exclusion due to incomplete answers
‡ Missing data for BMI in 5 patients (4.1%), sad or depressed for more than two weeks in 17 patients
(13.9 %), alcohol use in 3 patients (2.5%), no or little stress at home in 11 patients (9.0%), marital status 
in 3 patients (2.5%), high education in 4 patients (3.3%), EQ-5D-5L index in 5 patients (4.1%), 15D index 




   
 
   
 
   
  
   
   
   
   








    
 
     
    






     
    
  
    
   
    
    
 
Table 11. Multivariable binary logistic regression analysis for associations with 
depression/anxiety in EQ-5D-5L at 3 months (n=122).†. Reprinted from
Publication IV. Permission to reproduce granted by publishing terms by Wiley.
Variable OR (95% CI) P value
Sad or depressed for more 
than 2 weeks during the year
prior to ICH 
3.62 (1.14-11.45) 0.029
Dementia prior to ICH 16.65 (0.50-549.45) 0.11
DNR orders in hospital 4.87(0.99-23.95) 0.051
Stress at home prior to ICH 3.01 (0.86-10.58) 0.086
Baseline ICH volume 0.99 (0.96-1.03) 0.53
mRS 3-5 at 3 months 1.90 (0.75-4.80) 0.17
Abbreviations: DNR, do not resuscitate; ICH, intracerebral hemorrhage
† 102 patients included in analysis due to missing data
5.5 Publication V
Our cohort of 1013 ICH patients included 19 patients with occipital ICH, which
accounted for 5.3% of lobar and 1.9% of all ICH patients. Age was the only
baseline characteristic that differed between occipital ICH patients and other
ICH patients, occipital ICH patients being significantly younger with the
median age of 63 years (lobar 71 years, P=0.007; all 68 years, P=0.04). 
The occipital ICH patients had lower NIHSS and higher GCS than other
lobar ICH patients (median NIHSS 1 vs 8, P<0.001; median GCS 15 vs 14,
P<0.001) and other ICH patients (NIHSS 11, P<0.001; GCS 14, P<0.001).
Visual symptoms were prevalent (74% of occipital ICH patients), and 63% had
visual symptoms as their only neurological deficit. With visual field 
confrontation, 15 out of 18 patients had VFD. ICH volume was significantly
smaller in occipital ICH patients than other lobar ICH patients (6.3mL vs.
17.7mL, P=0.008). Amyloid angiopathy (53%) and structural lesions (26%)
were the most prevalent etiologies according to SMASH-U classification.
Occipital ICH patients had better outcomes than other ICH patients. The
median discharge mRS was 2 (IQR 1-2), 84% of the patients having mRS of 0-
2; compared to median mRS 4 (IQR 3-5), and mRS 0‒2 in 24% of patients
among non-occipital lobar ICH, and median mRS 5 (IQR 3-5), and mRS 0‒2 
in 17% of the patients among all ICH (P<0.001). Only one (5%) occipital ICH
patient died during hospital stay. One occipital ICH patient was lost to follow-
up, and none of the remaining 17 patients died during the follow-up time of 12 
months. Thus, 3- and 12-month mortality was 6% - significantly less than
among non-occipital lobar ICH patients at 12 months (34%, P=0.01) and
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among all non-occipital ICH patients at 3 and 12 months (33% and 37%,
P=0.02 and P=0.006). Occipital location had an independent association with
mRS 0-2 at discharge even when adjusted for strong predictors of outcome (OR
11.02, 95% CI 1.55‒78.20).
Eight occipital ICH patients reported residual visual impairments at
follow-up, and 10 patients had automated standard perimetry done within 7
months of their ICH. Six patients had VFD, and only 2 of them had a defect
that was a quadrant or larger. There were 7 patients that were not examined
with standard automated perimetry, and 6 of them had normal confrontation
perimetry at discharge or at follow-up visits. One year after ICH, 16 patients 
lived at home, and one lived in a nursing home. Two patients lost their driving 
license due to their neurological deficits, and 9 patients were allowed to drive 
a car. Five patients out of the 6 non-retired returned to work. Fourteen patients
had mRS of 0-2 at 3 and 12 months. The mRS of 2 patients at 3 months and 3
patients at 12 months could not be evaluated. Two (11%) occipital ICH patients
had seizures within 1 week of their ICH, whereas 20% of the non-occipital lobar
(P=0.55) and 11% of the non-occipital ICH (P>0.99) patients had early
seizures. Eighteen percent of the occipital ICH patients that were alive were
diagnosed having epilepsy after ICH, and the incidence was comparable to that
of non-occipital lobar ICH patients (16%, P=0.74), and bigger than all non-





     
   
         
  
  
         
        
    
   
     
   
  
  
          
  
 
    
 
   
      
    
  
   
         
 
       
   
   
   
    
6 Discussion
6.1 Main results in the context of existing literature
In this study, we wanted to assess ICH in a wide spectrum, from risk factors to
factors affecting the outcome of the patients. We wanted to find out novel
predictors for the risk of ICH, as well as such factors affecting outcome that are
not visible in the traditional outcome measures.
6.1.1 Risk factors of ICH (I)
We compared ICH patients to their stroke-free controls of similar age and sex. 
We also included assessment of fatigue and prior depressive feelings, and their
role as risk factors for ICH. Association of various psychological factors with
ICH risk is methodologically difficult to study, and includes a certain level of
subjectivity and higher possibility of bias, which might be the main reason for
the limited data on the subject. The INTERSTROKE study used a combined
measure of psychosocial factors combining stress, depression and life events,
and demonstrated that psychosocial factors were associated with ICH risk[5].
In our study, ICH patients reported significantly more often premorbid fatigue
than their controls. Premorbid feelings of depression were more common
among ICH patients than their controls, but the difference was no longer
significant in the multivariable analysis. 
In a Chinese cohort study, longer sleep duration, daytime napping, and
poor sleep quality were associated with higher risk of incident stroke. In that
study, there was no significant association with ICH and longer sleep duration
(˜ 9 hours) or daytime napping, however, the number of incident ICH was
much smaller than ischemic stroke, and the authors concluded that the
number might be too small to reach statistical significance[184], and longer
sleep duration has been found to associate with ICH[185]. One study found the 
association of ICH and sleep duration of 8 hours compared to 6-8 hours per
night only in women[186]. In a prospective study cohort, longer sleep duration
as well as a substantial increase in sleep time over the observation period were 
predictors for stroke[187]. Longer sleep duration has been associated with a 
number of conditions including inflammatory biomarkers[188], metabolic 
syndrome[189], and WMH volume[190]. We reasoned that the possible
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mechanisms might include a combination of underlying factors causing fatigue
(such as sleep apnea, other underlying diseases, and overall poor health), need
for longer resting, as well as different psychosocial factors. Depressive feelings
might also associate with overall poorer lifestyle factors, such as unhealthy diet
and less exercise, which might increase the risk for cardiovascular disease.
As previously found out, and also verified in our study among the under
70-year-olds, hypertension is a major risk factor for ICH[5,191–193]. In our
study, however, among the cohort of 70 years and older, the multivariable 
analysis did not show difference in hypertension between cases and controls.
We were not able to evaluate the exact reason for this. An earlier study also
showed differences in risk factors in different age groups, and in their study,
hypertension increased the risk for ICH only among patients under 70 years 
old[194]. We hypothesized that possibly other causes than hypertensive
angiopathy – such as amyloid angiopathy – play a larger role in the
pathological mechanisms of ICH in the older age group. Presumably, duration
of hypertension in years as well as severity of hypertension (the blood pressure 
values) have an effect on the risk of ICH. In our cohort, those parameters were 
not known.
We studied the possible association between alcohol consumption and risk
for ICH, defined as estimated amount of alcohol consumption per week, or any
alcohol use within the previous 12 months. The results between earlier studies
are somewhat conflicting, as in a rather large case-control study of 2660 ICH
cases and controls, up to moderate alcohol consumption reduced the risk of
ICH, whereas heavy alcohol consumption increased the risk for nonlobar ICH
in black and Hispanic, but not in white ICH patients[195]. Possibly, up to 
moderate alcohol consumption may also correlate with other healthy life-style
factors. A meta-analysis including 27 studies demonstrated that alcohol
consumption of up to 2 drinks/day associated with reduced risk of ischemic
stroke, and no association with ICH. Heavy alcohol consumption increased the
risk for both ischemic and hemorrhagic stroke[196].
As was the case with alcohol, we found no association with ICH and current
smoking or history of smoking. The same result has been reported in many of
the earlier studies[5,191,197,198]. However, some studies have reported
smoking to increase the risk for ICH[199,200].
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6.1.2 Triggering factors in ICH (II)
In this study on the possible association of triggering factors and ICH onset,
we found that a combination of physical triggers associated with the onset of 
ICH. However, the effect was fairly small, which may correlate with the
difficulties in receiving information from the acutely ill ICH patients, or reflect
a truly small effect of the triggering events. To our knowledge, this type of case-
crossover design has not been previously used to study if triggering factors can
be associated with the timing of ICH. A retrospective case series identified 16
ICH patients with different etiologies sought to investigate temporal
relationship between ICH and sexual intercourse, however no controls or case-
crossover design was used[201].
Case-crossover design has been previously used to study triggering events
preceding for example SAH[6,92], ischemic stroke[7,95], myocardial
infarction[202], and injuries[203]. In this type of design, the studied trigger
should be transient, and the onset time sudden[90]. In the setting of SAH,
drinking coffee or cola, vigorous physical exercise, nose blowing, straining for
defecation, being startled, anger, and sexual intercourse before the rupture of
an aneurysm could be identified as trigger factors to the hemorrhage, with
increased relative risk compared to the patients’ usual frequency of
exposure[92,93]. The effect was big enough to be identified in smaller
subcohorts of as few as 50-70 patients[92]. Among ischemic stroke patients,
negative emotions, anger, and sudden posture change due to startling
associated with the stroke onset time, whereas temperature change, positive
emotions, heavy eating, and physical exercise had no association[95].
As ICH and ischemic stroke have essentially different mechanisms (vessel
rupture vs. vessel occlusion), it is likely that the mechanisms of the triggering 
events are different. Many of the triggering events studied are linked to abrupt
elevation of blood pressure[96–98,204]. Catecholamine secretion has been 
suggested to be one of the mediators of the physiological effect on blood
pressure, heart rate, and myocardial oxygen demand caused by the triggering
event in the setting of cardiovascular events[99,100]. In our study, the actions
that associated to the ICH onset time were the combination of those which lead
to rapid and short-lasting rise in blood pressure. In ICH, it seems a plausible
explanation, that the association is driven by abruptly increased blood pressure
leading to a rupture of an already weakened vessel wall. As we could not
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identify any of the triggering events alone to be associated with ICH onset time,
it is likely that our sample size is too small, and possibly the effect is also
smaller than for example in SAH.
6.1.3 Hypocalcemia and ICH (III)
In our retrospective study on the association of hypocalcemia, ICH volume and
mortality, we showed that hypocalcemia was common (approximately 40% of
ICH patients), and that hypocalcemic patients had larger admission ICH
volumes and higher 90-day mortality. However, in a multivariable binary 
logistic regression analysis, hypocalcemia was not an independent predictor of
mortality, increased mortality among the hypocalcemic patients being likely
explained by the larger hematoma volumes.
Earlier studies have shown hypocalcemia to be a frequent finding in
critically ill patients, and its association with higher mortality[205], and
hypocalcemia has been suggested as possibly being a reflector of poor outcome.
Catecholamine-mediated translocation of plasma calcium into tissues and
increased fecal and/or urinary calcium excretion, and hyperadrenergic state 
associated with calcium derangement have been postulated as possible
mechanisms[205]. In our cohort, independent association with mortality was
not noted. However, as we included ICH volume, which is a strong and
independent predictor for mortality, in the multivariable model, the result was
not unexpected.
The association between hypocalcemia and larger ICH volumes has been 
reported also in previous studies[18,19]. Similarly with our study, Inoue et al.
did not find a significant association between hypocalcemia and mortality, 
after having adjusted for hematoma volume and NIHSS[18]. Morotti et al. did 
not include outcome analysis[19]. In a study by You et al., however, no
difference in hematoma volume was observed, but hypercalcemic patients had
better outcome[20]. In a study of 1262 ICH patients, published after our study, 
low serum calcium associated with poor outcome, and had an inverse linear
association with ICH volume[206]. Another study of 658 hypertensive ICH
patients published after our study also confirmed the association of lower
calcium level with larger hematoma volumes and worse outcome[207]. Taking 
into consideration several studies with results pointing in a similar direction,







        
   
   
 
    
   
   
  
     
  
     
    
         
      
     




      
       
   
 
    
       
          
    
 
   
    
outcome seems robust. However, whether hypocalcemia might have an
independent predictive value for worse outcome, when the effect of ICH
volume has been taken into account, was not shown in our study, and would
warrant further research, possibly using a prospective setting, and including
all possible known parameters that might affect calcium levels, such as vitamin
D status and kidney function.
In addition to calcium, magnesium – another mediator in coagulation –
has been shown to affect hematoma volume in ICH patients, as patients with
lower magnesium levels having been shown to have larger hematoma volumes 
and greater hematoma expansion presumably due to coagulopathy, platelet 
dysfunction, higher blood pressure, and inflammatory response[208]. In the
setting of ischemic stroke, a genetic study on causal association of serum 
magnesium and calcium concentrations with stroke risk found that genetically
higher serum magnesium concentrations associated with a reduced risk of
cardioembolic stroke. For calcium, there was no association[209]. The finding
outlines the complexity of the matter – the complex interplay of genetic and
environmental factors affecting both the risk for disease as well as the outcome.
The proposed mechanisms for hypocalcemic patients having larger
hematoma volumes as most of the studies imply, have been calcium’s effect on
coagulation and the association with blood pressure. However, in the study of
Morotti et al.[19], there was no significant difference in blood pressure
between hypocalcemic and normocalcemic patients, as was the case in our
study. Additionally, hypocalcemia possibly reflecting poor liver function, and
thus affecting coagulation has been suggested as a possible mechanism[18]. In 
our study, hypocalcemic patients had not significantly more often liver disease.
In the setting of bleeding patients, the alterations in hemostasis have been 
thought to be partly caused by hypocalcemia, and to contribute to morbidity
and mortality[210]. Thus, the proposed association of hypocalcemia with 
coagulation and larger hematoma volumes seems reasonable.
As the calcium levels before ICH are not known, another explanation might
be that the neuronal damage caused by the hematoma would lower the calcium
concentration in the blood. Thus, patients with larger hematomas would have
larger amount of calcium drawn from the extracellular spaces to the cells, and
hypocalcemia would be rather the result of a large ICH volume than its cause.
Animal studies have demonstrated that ischemia in neurons causes prolonged
68
 




   
 
       
  
      







     







   
  
  
       
  
  
       
         
 
calcium influx from extracellular sources to the cells[211]. An experimental
ICH model in cats demonstrated a longstanding loss of calcium ions in the 
extracellular space, the ionic movement also taking place in the cells that were 
not directly damaged[212], implying to the role of endothelial dysfunction in 
the context of neuronal cell damage and hypocalcemia. The pathophysiology
may be complex, and it is possible that alterations in blood calcium levels are
secondary to dysfunction in the parathyroid hormone-vitamin D axis following
acute immune response in ICH[213].
In our cohort, the median time from ICH onset time to imaging was longer
in the hypocalcemic group (median 3.5 hours, IQR 1.6-9.8 vs. 2.1 hours, IQR
1.4-4.8; p=0.002). However, time did not predict independently ICH volume
in linear multivariable analysis.
6.1.4 Quality of life after ICH (IV) 
In our substudy on health-related quality of life, baseline stroke severity and
ICH volume were strongly associated with HRQoL three months after ICH.
Asthma/COPD and chronic heart failure were predictors for worse quality of
life, as also earlier studies have implied[214,215]. Older age had an
independent association with diminished quality of life – as also seen in the
general population[183].
Twenty-one (17.2%) of the 122 patients included in the analysis on 
depressive symptoms after ICH reported having been feeling depressed for
more than 2 weeks during the year prior to ICH. However, only 4 (3.7%)
patients had been receiving antidepressant medication and only one (0.9%) 
patient psychotherapy, implying possibly underrecognition and
undertreatment of depression. Feelings of depression as measured by the
depression/anxiety domain of the EQ-5D-5L questionnaire were more
frequently reported by patients with higher mRS as an indicator of worse
functional outcome. However, of the tested parameters, only feeling sad or
depressed before ICH predicted feelings of depression/anxiety at three months
after ICH. Similarly, also among subarachnoid hemorrhage (SAH) patients,
pre-SAH depression and premorbid psychosocial stress were predictors for
depression at three months after SAH[216]. Among ICH patients in our cohort,










   
   
    
     
  
          
 
  
   
    
 
         
   
   
   
  
    
    
 
  
    
 
       
  
In our study, patients with pre-ICH dementia were few, but all of them
reported feelings of depression/anxiety after ICH. Indeed, dementia patients
have been reported to frequently have depression[217]. However, as pre-ICH 
dementia was rare in our cohort, a significant association between dementia
and depression was not noted.
A multi-center study on depression after ICH concluded that depression
among ICH patients is common, but may remain underrecognized. Only less 
than 10% of the patients with depressive symptoms received any commonly
used antidepressive medication[218]. Especially, as post-ICH depression has
been shown to have a negative influence on patients’ outcome that is not 
related to initial hemorrhage severity[177], diagnosing and treating depression
could have widespread influence in patients functioning and reducing 
suffering after ICH. Our results imply that simple questions on premorbid
feelings of depression could be one tool to help finding patients at risk for post-
stroke depression.
6.1.5 Occipital ICH (V)
In our study, occipital location was rare compared to other locations, occipital
ICH consisting of 5.3% of lobar and 1.9% of all ICH. The hemorrhage volumes
were smaller than in other lobar locations, and structural etiology was more
common. The functional status of the patients at discharge was better, and less
patients died within 12 months. However, in multivariable analysis the
difference in mortality was not significant, and the confidence intervals were 
wide, probably due to the small number of occipital ICH patients. Risk of
symptomatic epilepsy was the same as for the other locations. The smaller
prevalence (even when adjusted with the size of the lobes) and volume of
occipital ICH, as well as least growth in the size of the hematoma have been 
described earlier[219]. It has been hypothesized[219] that the smaller volume
and growth might be linked to higher gray/white-matter ratio[220] and lower
arterial pressure gradient[221].
Visual field defect was the most prevalent symptom in the acute phase
(over 80% of occipital ICH patients), which is not surprising as the cohort was
limited to patients having ICH in the lobe that harbors vision-related
structures. Approximately 50% continued to having residual visual symptoms.












        
  
             
    
   
  
   
  
 
         
    
   
 
 




    
 
 
   
      
   
    
were examined with standard automated perimetry, and VFD may go
unrecognized by the patient as well as by medical personnel[222,223].
In our cohort of occipital ICH patients, structural etiology was more
common compared to ICH in other locations, which likely correlates with the
better outcome, as well as the younger age of the patients. Structural etiology
(by SMASH-U classification) has been shown to have the most favorable
outcome among ICH patients[14]. Previously, occipital location has been
shown to predict good functional outcome at 3 months[219]. The outcome of
occipital ICH patients seemed better by also robust measurements such as
mortality, and return to work - as evaluation of solely mRS can lead to
underestimation of visual and possibly cognitive symptoms. Studies on
ischemic stroke have shown that damage to the white matter might be essential
in predicting poor functional outcome after stroke[224]. Thus, if the
gray/white matter ratio has a role in the interplay of hematoma location, 
volume and prognosis, damage to the white matter might be essential.
6.2 Strengths and limitations
The strength of our study includes a homogenous cohort, as a vast majority of
the patients are ethnic Finns. For the evaluation on quality of life we used two
different methods (15D and EQ-5D-5L questionnaires). Case cross-over design
(Publication II) leads to no selection bias, each case serving as its own control.
The patients were interviewed face-to-face, and thus we could evaluate if the 
patient was able to provide consistent answers, and the orientation was
sufficient for the interview.
For publication III (hypocalcemia) one of the strengths is using the ionized
calcium, which is better for reflecting physically active calcium[225]. Most
patients were admitted shortly after stroke (within the first hours). For
analyzing the most relevant values, the timing between admission, laboratory
testing and imaging were relatively short and limited.
The limitations include the rather small cohort as well as the amount of
missing data in the prospective part of the study. Due to the nature of the 
illness, many patients had aphasia, depressed level of consciousness, or
confusion, and were not able to provide answers to the questions. Many of the
parameters of quality of life are subjective, and difficult to measure. As
expected, the patients participating in reporting and interviewing, were more
71
 
      
   
    
        
  
   
    
 
       
 
       
             
  
  
    
    
      
 
 
       






     
      
  
    
  
          
  
mildly affected than the non-participants. The pre-ICH feelings such as fatigue
and feelings of depression could be questioned only after ICH, and thus it is
possible that the present feelings affect the answers on past feelings. Obviously,
a diagnosis of pre-ICH depression cannot be made by our questionnaire. In the 
substudy on risk factors (I), the eldest controls were 74-year-olds, and thus 
significantly younger than the cases. The cases and controls were compared in
several age groups: all, under 70-year-olds, and 70 years and older. Thus, only 
in the younger age group, the ages of cases and controls were similar. The
participants were mainly habitants of the Uusimaa region, whereas the control
population could not be limited to the Uusimaa region to get an adequate 
number of controls. Unfortunately, many parameters in the questionnaires for
cases and controls were not comparable and had to be left out of our study. The
question on regularity of fatigue was also questioned using different terms for
cases and controls, and had to be re-classified. Obviously, this might cause
some unreliability in the results.
For publications III (hypocalcemia) and V (Occipital ICH) the 
retrospective nature of the study was a limitation. Even though the patients in
the original cohort were consecutive, there was a large number of patients
without calcium testing, as testing calcium routinely did not belong to the 
protocol in our center. It cannot be ruled out that selection bias would exist for
measuring calcium for certain patients. As we had no certain time point for
control imaging, and all patients did not have follow-up imaging, ICH growth
could not be assessed. As functional outcome of the patients was not known,
we were not able to study the effect of hypocalcemia to functional recovery.
For occipital ICH patients, the mRS was defined retrospectively, and even
though the electronic medical files are extensive in Finland, the mRS needed
to be grouped, and for every patient it was not possible to reconstruct the exact 
mRS value at a certain time point. The patients were not routinely screened for
VFD by standard automated perimetry. As the number of occipital ICH
patients was small, the statistical analyses are less reliable.
6.3 Implications for future research
As our cohort was rather small, it would be interesting to combine ICH patients
from different parts of Finland for a risk factor analysis, and possibly with a 
wider set of questions that would correspond to the already-existing FINRISK
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study. Also for the trigger study, a multicenter study reaching a substantially 
larger patient number would bring additional power to the analyses. 
Interesting topic for future research would be to analyze the effect of
hypocalcemia and its causes more thoroughly in a prospective setting, ideally
taking into consideration the level prior to index ICH. More extensive 
laboratory testing in order to evaluate the causes of hypocalcemia could be
done (including vitamin D as well as parathyroid hormone). The timing of the
laboratory testing could be as early as possible, preferably before intravenous 
fluid administration, and possibly include repeated laboratory sampling to find
out how time effects the calcium values. Better evaluation of functional
recovery could be evaluated as well as testing if and how correction of
hypocalcemia has any effect on patients’ prognosis.
The relationship of depression before and after ICH would be interesting
to perform in a larger cohort of ICH patients, and include more thorough
testing of depression, including a structured evaluation of the symptoms, such




       











      
         
   
 
    
    




Of the studied risk factors, hypertension was associated with risk of ICH among
all patients and in the group of patients under 70 years of age. Fatigue prior to 
ICH was more common among all ICH cases, which might be linked to a 
combination of underlying factors causing fatigue (such as sleep apnea), need
for longer resting and different psychosocial factors.
We found that physical triggers i.e. factors that raise blood pressure
abruptly, associate with the timing of ICH, potentially serving as triggering
factors for ICH.
Admission hypocalcemia associated with larger ICH volumes. Patients 
with admission hypocalcemia had a higher 90-day mortality compared to
normocalcemic patients (53.1% vs. 34.5%), due to their larger ICH volumes.
Stroke severity, comorbidities and age were associated with HRQoL after
ICH. Feelings of depression before ICH had a stronger influence on reporting
depression/anxiety after ICH than stroke severity-related and outcome
parameters. Simple questioning of premorbid feelings of depression could help
identify ICH patients at risk for depression.
Compared to other ICH patients, occipital ICH was less frequent, the
patients were younger, had milder neurological deficits, smaller ICH volumes,
more often structural etiology, and better outcomes. The risk for epilepsy was,
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